

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:50:18 ON 06 JUN 2003

=> fil .bec

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

FULL ESTIMATED COST

| | |
|------|------|
| 0.21 | 0.21 |
|------|------|

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODASE, BIOTECHNO, WPIDS' ENTERED AT 10:50:38 ON 06 JUN 2003
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s dna(w) (pk or activated(w) (protein kinase# or pk))

FILE 'MEDLINE'

694237 DNA
134256 PK
190484 ACTIVATED
1161323 PROTEIN
190849 KINASE#
92078 PROTEIN KINASE#
(PROTEIN(W) KINASE#)
134256 PK

L1 680 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'SCISEARCH'

480933 DNA
16920 PK
202879 ACTIVATED
995241 PROTEIN
213447 KINASE#
107420 PROTEIN KINASE#
(PROTEIN(W) KINASE#)
16920 PK

L2 524 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'LIFESCI'

229692 DNA
4313 PK
71872 ACTIVATED
403015 "PROTEIN"
62069 KINASE#
30432 PROTEIN KINASE#
("PROTEIN" (W) KINASE#)
4313 PK

L3 334 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'BIOTECHDS'

99133 DNA
251 PK
10507 ACTIVATED
101746 PROTEIN
6520 KINASE#
1168 PROTEIN KINASE#
(PROTEIN(W) KINASE#)
251 PK

L4 6 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'BIOSIS'

701206 DNA
14718 PK
219476 ACTIVATED

```

1297795 PROTEIN
243329 KINASE#
112764 PROTEIN KINASE#
      (PROTEIN(W) KINASE#)
14718 PK
L5      575 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'EMBASE'
      511309 DNA
      146991 PK
      190545 ACTIVATED
1113247 "PROTEIN"
      164715 KINASE#
      84253 PROTEIN KINASE#
            ("PROTEIN" (W) KINASE#)
      146991 PK
L6      474 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'HCAPLUS'
      612489 DNA
      20957 PK
      407484 ACTIVATED
1516037 PROTEIN
      200733 KINASE#
      93976 PROTEIN KINASE#
            (PROTEIN(W) KINASE#)
      20957 PK
L7      538 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'NTIS'
      8508 DNA
      362 PK
      9722 ACTIVATED
11926 PROTEIN
      1366 KINASE#
      449 PROTEIN KINASE#
            (PROTEIN(W) KINASE#)
      362 PK
L8      10 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'ESBIOBASE'
      207714 DNA
      6175 PK
      86664 ACTIVATED
458809 PROTEIN
      85258 KINASE#
      49964 PROTEIN KINASE#
            (PROTEIN(W) KINASE#)
      6175 PK
L9      431 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'BIOTECHNO'
      363454 DNA
      4472 PK
      85314 ACTIVATED
572356 PROTEIN
      83617 KINASE#
      43669 PROTEIN KINASE#
            (PROTEIN(W) KINASE#)
      4472 PK
L10     351 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

FILE 'WPIDS'
      48719 DNA

```

1508 PK
115820 ACTIVATED
98077 PROTEIN
7134 KINASE#
1939 PROTEIN KINASE#
 (PROTEIN(W) KINASE#)
1508 PK
L11 17 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

TOTAL FOR ALL FILES

L12 3940 DNA(W) (PK OR ACTIVATED(W) (PROTEIN KINASE# OR PK))

=> s l12 not 1994-1996/py

FILE 'MEDLINE'

1244236 1994-1996/PY

L13 581 L1 NOT 1994-1996/PY

FILE 'SCISEARCH'

2559592 1994-1996/PY

L14 438 L2 NOT 1994-1996/PY

FILE 'LIFESCI'

325401 1994-1996/PY

L15 275 L3 NOT 1994-1996/PY

FILE 'BIOTECHDS'

46905 1994-1996/PY

L16 6 L4 NOT 1994-1996/PY

FILE 'BIOSIS'

1660749 1994-1996/PY

L17 485 L5 NOT 1994-1996/PY

FILE 'EMBASE'

1117373 1994-1996/PY

L18 398 L6 NOT 1994-1996/PY

FILE 'HCAPLUS'

2256014 1994-1996/PY

L19 461 L7 NOT 1994-1996/PY

FILE 'NTIS'

131755 1994-1996/PY

L20 8 L8 NOT 1994-1996/PY

FILE 'ESBIOBASE'

498223 1994-1996/PY

L21 367 L9 NOT 1994-1996/PY

FILE 'BIOTECHNO'

304425 1994-1996/PY

L22 291 L10 NOT 1994-1996/PY

FILE 'WPIDS'

1732428 1994-1996/PY

L23 17 L11 NOT 1994-1996/PY

TOTAL FOR ALL FILES

L24 3327 L12 NOT 1994-1996/PY

=> s l24 not 1997-1999/py

FILE 'MEDLINE'

1333570 1997-1999/PY

L25 317 L13 NOT 1997-1999/PY

FILE 'SCISEARCH'
2862496 1997-1999/PY
L26 240 L14 NOT 1997-1999/PY

FILE 'LIFESCI'
337226 1997-1999/PY
L27 130 L15 NOT 1997-1999/PY

FILE 'BIOTECHDS'
41038 1997-1999/PY
L28 6 L16 NOT 1997-1999/PY

FILE 'BIOSIS'
1680795 1997-1999/PY
L29 282 L17 NOT 1997-1999/PY

FILE 'EMBASE'
1252969 1997-1999/PY
L30 207 L18 NOT 1997-1999/PY

FILE 'HCAPLUS'
2535538 1997-1999/PY
L31 263 L19 NOT 1997-1999/PY

FILE 'NTIS'
85373 1997-1999/PY
L32 7 L20 NOT 1997-1999/PY

FILE 'ESBIOBASE'
831730 1997-1999/PY
L33 184 L21 NOT 1997-1999/PY

FILE 'BIOTECHNO'
338670 1997-1999/PY
L34 143 L22 NOT 1997-1999/PY

FILE 'WPIDS'
2351312 1997-1999/PY
L35 16 L23 NOT 1997-1999/PY

TOTAL FOR ALL FILES
L36 1795 L24 NOT 1997-1999/PY

=> s l36 not 2000-2003/py

FILE 'MEDLINE'
1724843 2000-2003/PY
L37 23 L25 NOT 2000-2003/PY

FILE 'SCISEARCH'
3248680 2000-2003/PY
L38 24 L26 NOT 2000-2003/PY

FILE 'LIFESCI'
326324 2000-2003/PY
L39 11 L27 NOT 2000-2003/PY

FILE 'BIOTECHDS'
60540 2000-2003/PY
L40 0 L28 NOT 2000-2003/PY

FILE 'BIOSIS'
1778159 2000-2003/PY
L41 33 L29 NOT 2000-2003/PY

FILE 'EMBASE'
1483306 2000-2003/PY
L42 18 L30 NOT 2000-2003/PY

FILE 'HCAPLUS'
3283625 2000-2003/PY
L43 21 L31 NOT 2000-2003/PY

FILE 'NTIS'
53037 2000-2003/PY
L44 2 L32 NOT 2000-2003/PY

FILE 'ESBIOBASE'
948733 2000-2003/PY
L45 0 L33 NOT 2000-2003/PY

FILE 'BIOTECHNO'
388989 2000-2003/PY
L46 13 L34 NOT 2000-2003/PY

FILE 'WPIDS'
2930742 2000-2003/PY
L47 0 L35 NOT 2000-2003/PY

TOTAL FOR ALL FILES
L48 145 L36 NOT 2000-2003/PY

=> dup rem l48
PROCESSING COMPLETED FOR L48
L49 46 DUP REM L48 (99 DUPLICATES REMOVED)

=> d tot

L49 ANSWER 1 OF 46 MEDLINE DUPLICATE 1
TI The carboxyl-terminal transactivation domain of human serum response factor contains **DNA-activated protein kinase** phosphorylation sites.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1993 Oct 5) 268 (28) 21147-54. Journal code: 2985121R. ISSN: 0021-9258.
AU Liu S H; Ma J T; Yueh A Y; Lees-Miller S P; Anderson C W; Ng S Y
AN 94012665 MEDLINE

L49 ANSWER 2 OF 46 MEDLINE
TI Characterization of protein kinase activities associated with p53-large-T immune complexes from SV40-transformed rat cells.
SO ONCOGENE, (1993 Aug) 8 (8) 2193-205. Journal code: 8711562. ISSN: 0950-9232.
AU Muller E; Boldyreff B; Scheidtmann K H
AN 93330560 MEDLINE

L49 ANSWER 3 OF 46 MEDLINE DUPLICATE 2
TI Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression.
SO ONCOGENE, (1993 Jun) 8 (6) 1519-28. Journal code: 8711562. ISSN: 0950-9232.
AU Fiscella M; Ullrich S J; Zambrano N; Shields M T; Lin D; Lees-Miller S P; Anderson C W; Mercer W E; Appella E
AN 93275646 MEDLINE

L49 ANSWER 4 OF 46 MEDLINE DUPLICATE 3
TI c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro; definition of the minimal kinase recognition motif.
SO NUCLEIC ACIDS RESEARCH, (1993 Mar 11) 21 (5) 1289-95.

Journal code: 0411011. ISSN: 0305-1048.

AU Bannister A J; Gottlieb T M; Kouzarides T; Jackson S P
AN 93219094 MEDLINE

L49 ANSWER 5 OF 46 MEDLINE
TI Transcription factor phosphorylation by the DNA-dependent protein kinase.
SO BIOCHEMICAL SOCIETY TRANSACTIONS, (1993 Nov) 21 (4) 930-5. Ref: 38
Journal code: 7506897. ISSN: 0300-5127.
AU Finnie N; Gottlieb T; Hartley K; Jackson S P
AN 94178642 MEDLINE

L49 ANSWER 6 OF 46 MEDLINE DUPLICATE 4
TI Stimulation of phosphorylation of a nuclear protein (NP-34) in cultured Alzheimer's disease (AD) fibroblasts by interferon response element and other double-stranded oligonucleotides.
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, (1993 Jul) 30 (4) 675-84.
Journal code: 9306673. ISSN: 1039-9712.
AU An S; Maturana J; Wu J M
AN 94004608 MEDLINE

L49 ANSWER 7 OF 46 MEDLINE DUPLICATE 5
TI DNA damage and the **DNA-activated protein kinase**.
SO TRENDS IN BIOCHEMICAL SCIENCES, (1993 Nov) 18 (11) 433-7. Ref: 32
Journal code: 7610674. ISSN: 0968-0004.
AU Anderson C W
AN 94120555 MEDLINE

L49 ANSWER 8 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI **DNA-ACTIVATED PROTEIN-KINASE** IN
RAJI BURKITT-LYMPHOMA CELLS - PHOSPHORYLATION OF NUCLEAR-PROTEIN FACTORS INVOLVED IN DNA-REPLICATION AND TRANSCRIPTION
SO JOURNAL OF CELLULAR BIOCHEMISTRY, (09 JAN 1993) Supp. 17A, pp. 305.
ISSN: 0730-2312.
AU TERAOKA H (Reprint); WATANABE F; MINAMI H; IIJIMA S; TSUKADA K; DATE T; KITAJIMA S
AN 93:124123 SCISEARCH

L49 ANSWER 9 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **DNA-activated protein kinase** in
Raji Burkitt's lymphoma cells: Phosphorylation of nuclear protein factors involved in DNA replication and transcription.
SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART A, pp. 305.
Meeting Info.: Keystone Symposium on Phosphorylation/Dephosphorylation in Signal Transduction Keystone, Colorado, USA January 17-24, 1993
ISSN: 0733-1959.
AU Teraoka, Hirobumi (1); Watanabe, Fumiaki (1); Minami, Hanae (1); Iijima, Shigeyuki (1); Tsukada, Kinji (1); Date, Takayasu; Kitajima, Shigetaka (1)
AN 1993:181735 BIOSIS

L49 ANSWER 10 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI ACTIVITY OF THE DNA-DEPENDENT PROTEIN-KINASE (**DNA-PK**)
MAY REQUIRE 2 DISTINCT PROTEINS
SO JOURNAL OF CELLULAR BIOCHEMISTRY, (09 JAN 1993) Supp. 17A, pp. 304.
ISSN: 0730-2312.
AU SUN S S (Reprint); MALIK N P; LUGOAYALA E; VANCUROVA I; CARTER T H
AN 93:124122 SCISEARCH

L49 ANSWER 11 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Activity of the DNA-dependent protein kinase (**DNA-PK**)
may require two distinct proteins.
SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART A,

pp. 304.

Meeting Info.: Keystone Symposium on Phosphorylation/Dephosphorylation in Signal Transduction Keystone, Colorado, USA January 17-24, 1993

ISSN: 0733-1959.

AU Sun, Shi-Shin; Malik, Nusrat Parveen; Vancurova, Elissa Vv Lugo-Ayalaana; Carter, Timothy H.

AN 1993:181734 BIOSIS

L49 ANSWER 12 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 6
TI IDENTIFICATION AND CLONING OF DNA-SEQUENCES THAT BIND AND ACTIVATE THE DNA-DEPENDENT PROTEIN-KINASE (**DNA-PK**)

SO JOURNAL OF CELLULAR BIOCHEMISTRY, (09 JAN 1993) Supp. 17A, pp. 301.

ISSN: 0730-2312.

AU MALIK N P (Reprint); POLTORATSKY V; VANCUROVA I; CARTER T H

AN 93:124107 SCISEARCH

L49 ANSWER 13 OF 46 MEDLINE

TI Phosphorylation of transcription factor Sp1 by the DNA-dependent protein kinase.

SO ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH, (1993) 28 279-86. Ref: 27

Journal code: 8807408. ISSN: 1040-7952.

AU Jackson S; Gottlieb T; Hartley K

AN 94001138 MEDLINE

L49 ANSWER 14 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI

TI THE KU (P70/P80) PROTEIN ASSEMBLES INTO AN AUTOIMMUNOGENIC COMPLEX WITH THE 350 KDA CATALYTIC POLYPEPTIDE OF DNA-DEPENDENT PROTEIN-KINASE (**DNA-PK**)

SO CLINICAL RESEARCH, (APR 1993) Vol. 41, No. 2, pp. A187.

ISSN: 0009-9279.

AU SUWA A (Reprint); HIRAKATA M; TAKEDA Y; MIMORI T; HARDIN J A

AN 93:227715 SCISEARCH

L49 ANSWER 15 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI The Ku (p70/p80) protein assembles into an autoimmunogenic complex with the 350 kDa catalytic polypeptide of DNA-dependent protein kinase (**DNA-PK**).

SO Clinical Research, (1993) Vol. 41, No. 2, pp. 187A.

Meeting Info.: Joint Meeting of the Association of American Physicians, the American Society for Clinical Investigation, and the American Federation for Clinical Research Washington, DC, USA April 30-May 3, 1993
ISSN: 0009-9279.

AU Suwa, A. (1); Hirakata, M.; Takeda, Y.; Mimori, T.; Hardin, J. A.

AN 1993:293076 BIOSIS

L49 ANSWER 16 OF 46 MEDLINE

DUPLICATE 7

TI **DNA-activated protein kinase.**

SO TANPAKUSHITSU KAKUSAN KOSO. PROTEIN, NUCLEIC ACID, ENZYME, (1993 Feb) 38 (2) 158-65. Ref: 28

Journal code: 0413762. ISSN: 0039-9450.

AU Iijima S; Teraoka H

AN 93197559 MEDLINE

L49 ANSWER 17 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 8

TI PHOSPHORYLATION OF THE P53 TUMOR SUPPRESSOR PROTEIN BY THE **DNA-ACTIVATED PROTEIN-KINASE**

SO JOURNAL OF CELLULAR BIOCHEMISTRY, (13 MAR 1993) Supp. 17D, pp. 157.
ISSN: 0730-2312.

AU ANDERSON C W (Reprint); LEESMILLER S P; LIN D; MERCER W E; SAKAGUCHI K; FISCELLA M; ULLRICH S; APPELLA E

AN 93:220194 SCISEARCH

L49 ANSWER 18 OF 46 MEDLINE

DUPLICATE 9

TI The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.
 SO CELL, (1993 Jan 15) 72 (1) 131-42.
 Journal code: 0413066. ISSN: 0092-8674.
 AU Gottlieb T M; Jackson S P
 AN 93137321 MEDLINE

L49 ANSWER 19 OF 46 MEDLINE DUPLICATE 10
 TI Phosphorylation of a 72-kDa nucleoprotein (NP-72) in HL-60 cells is mediated by the double-stranded DNA-dependent protein kinase (**DNA-PK**).
 SO BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, (1993 Sep) 31 (1) 113-24.
 Journal code: 9306673. ISSN: 1039-9712.
 AU Konno-Sato S; Wu J M; Carter T H
 AN 94083934 MEDLINE

L49 ANSWER 20 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI
 TI BINDING OF KU-DEPENDENT AND DNA-DEPENDENT PROTEIN-KINASE (**DNA-PK**) TO A NOVEL CHROMOSOMAL RECEPTOR
 SO ARTHRITIS AND RHEUMATISM, (SEP 1993) Vol. 36, No. 9, Supp. S, pp. S72. ISSN: 0004-3591.
 AU SATOH M (Reprint); AJMANI A K; REEVES W H
 AN 93:639432 SCISEARCH

L49 ANSWER 21 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 TI Binding of ku and DNA-dependent protein kinase (**DNA-PK**) to a novel chromosomal receptor.
 SO Arthritis and Rheumatism, (1993) Vol. 36, No. 9 SUPPL., pp. S72. Meeting Info.: 57th Annual Scientific Meeting of the American College of Rheumatology San Antonio, Texas, USA November 7-11, 1993
 ISSN: 0004-3591.
 AU Satoh, Minoru; Ajmani, Ajay K.; Reeves, Westley H.
 AN 1994:9088 BIOSIS

L49 ANSWER 22 OF 46 MEDLINE DUPLICATE 11
 TI Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens.
 SO MOLECULAR BIOLOGY REPORTS, (1993 Jun) 18 (1) 15-28.
 Journal code: 0403234. ISSN: 0301-4851.
 AU Wang J; Chou C H; Blankson J; Satoh M; Knuth M W; Eisenberg R A; Pisetsky D S; Reeves W H
 AN 94049782 MEDLINE

L49 ANSWER 23 OF 46 MEDLINE DUPLICATE 12
 TI Phosphorylation of protein tau by double-stranded DNA-dependent protein kinase.
 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1993 May 28) 193 (1) 13-8.
 Journal code: 0372516. ISSN: 0006-291X.
 AU Wu J M; Chen Y; An S; Perruccio L; Abdel-Ghany M; Carter T H
 AN 93277540 MEDLINE

L49 ANSWER 24 OF 46 MEDLINE DUPLICATE 13
 TI Human **DNA-activated protein kinase** phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53.
 SO MOLECULAR AND CELLULAR BIOLOGY, (1992 Nov) 12 (11) 5041-9.
 Journal code: 8109087. ISSN: 0270-7306.
 AU Lees-Miller S P; Sakaguchi K; Ullrich S J; Appella E; Anderson C W
 AN 93024450 MEDLINE

L49 ANSWER 25 OF 46 MEDLINE DUPLICATE 14
 TI Phosphorylation sites in the amino-terminal region of mouse p53.

SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1992 May 15) 89 (10) 4231-5.
Journal code: 7505876. ISSN: 0027-8424.

AU Wang Y; Eckhart W
AN 92262414 MEDLINE

L49 ANSWER 26 OF 46 MEDLINE DUPLICATE 15
TI **DNA-activated protein kinase** in
Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.

SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (1992 Jun 1) 206 (2) 595-603.
Journal code: 0107600. ISSN: 0014-2956.

AU Iijima S; Teraoka H; Date T; Tsukada K
AN 92283288 MEDLINE

L49 ANSWER 27 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI SURFACE-ENHANCED RAMAN-SPECTROSCOPY OF ELLIPTICINE, 2-N-METHYLELLIPTICINIUM AND THEIR COMPLEXES WITH DNA

SO JOURNAL OF RAMAN SPECTROSCOPY, (JUL 1992) Vol. 23, No. 7, pp. 373-377.
ISSN: 0377-0486.

AU AUBARD J (Reprint); SCHWALLER M A; PANTIGNY J; MARSAULT J P; LEVI G
AN 92:447455 SCISEARCH

L49 ANSWER 28 OF 46 MEDLINE DUPLICATE 16
TI The nuclear serine/threonine protein kinase **DNA-PK**.

SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, (1992) 2 (4) 283-314.
Ref: 187
Journal code: 9007261. ISSN: 1045-4403.

AU Anderson C W; Lees-Miller S P
AN 93136568 MEDLINE

L49 ANSWER 29 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI HUMAN SERUM RESPONSE FACTOR SRF IS PHOSPHORYLATED BY THE **DNA-ACTIVATED PROTEIN KINASE DNA-PK**.

SO KEYSTONE SYMPOSIUM ON POSITIVE GROWTH CONTROL, KEYSTONE, COLORADO, USA, JANUARY 26-FEBRUARY 2, 1992. J CELL BIOCHEM SUPPL. (1992) 0 (16 PART B), 242.
CODEN: JCBSD7.

AU NG S-Y; LIU S-H; MA J-T; CHIANG S-H; LEES-MILLER S P; ANDERSON C W
AN 1992:293572 BIOSIS

L49 ANSWER 30 OF 46 LIFESCI COPYRIGHT 2003 CSA
TI The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen.

SO CELL., (1992) vol. 72, no. 1, pp. 131-142.

AU Gottlieb, T.M.; Jackson, S.P.
AN 93:64479 LIFESCI

L49 ANSWER 31 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 17
TI STIMULATION OF PHOSPHORYLATION OF A NUCLEAR-PROTEIN (NP-72) IN CONTROL AND TPA TREATED HL-60 CELLS BY VARIOUS DSDNA OLIGONUCLEOTIDES IN THE PRESENCE OF DSDNA DEPENDENT PROTEIN-KINASE (**DNA-PK**)

SO FASEB JOURNAL, (01 JAN 1992) Vol. 6, No. 1, pp. A69.
ISSN: 0892-6638.

AU YESUS K G (Reprint); MATURANA J A; KONNO S; CARTER T H; WU J M
AN 92:39334 SCISEARCH

L49 ANSWER 32 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI STIMULATION OF PHOSPHORYLATION OF A NUCLEAR PROTEIN NP-72 IN CONTROL AND TPA TREATED HL-60 CELLS BY VARIOUS DSDNA OLIGONUCLEOTIDES IN THE PRESENCE OF DSDNA DEPENDENT PROTEIN KINASE **DNA-PK**.

SO JOINT ANNUAL MEETING OF THE BIOPHYSICAL SOCIETY AND THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, HOUSTON, TEXAS, USA, FEBRUARY 9-13, 1992. BIOPHYS J. (1992) 61 (2 PART 2), A69.

CODEN: BIOJAU. ISSN: 0006-3495.

AU YESUS K G; MATURANA J A; KONNO S; CARTER T H; WU J M
AN 1992:201601 BIOSIS

L49 ANSWER 33 OF 46 MEDLINE DUPLICATE 18
TI Chicken progesterone receptor is phosphorylated by a DNA-dependent protein kinase during in vitro transcription assays.
SO MOLECULAR ENDOCRINOLOGY, (1992 Jan) 6 (1) 8-14.
Journal code: 8801431. ISSN: 0888-8809.
AU Weigel N L; Carter T H; Schrader W T; O'Malley B W
AN 92149580 MEDLINE

L49 ANSWER 34 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY VOL. 12.
SO JEANTEUR, P., ET AL. (ED.). PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY, VOL. 12. IX+137P. SPRINGER-VERLAG: BERLIN, GERMANY; NEW YORK, NEW YORK, USA. ILLUS. (1991) 0 (0), IX+137P.
CODEN: PMSBA4. ISSN: 0079-6484. ISBN: 3-540-53900-X, 0-387-53900-X.
AU JEANTEUR P; ET AL
AN 1992:378112 BIOSIS

L49 ANSWER 35 OF 46 MEDLINE DUPLICATE 19
TI The human **DNA-activated protein kinase** phosphorylates simian virus 40 T antigen at amino- and carboxy-terminal sites.
SO JOURNAL OF VIROLOGY, (1991 Oct) 65 (10) 5131-40.
Journal code: 0113724. ISSN: 0022-538X.
AU Chen Y R; Lees-Miller S P; Tegtmeyer P; Anderson C W
AN 91374560 MEDLINE

L49 ANSWER 36 OF 46 MEDLINE DUPLICATE 20
TI The **DNA-activated protein kinase**, **DNA-PK**: a potential coordinator of nuclear events.
SO CANCER CELLS, (1991 Sep) 3 (9) 341-6. Ref: 34
Journal code: 9000382. ISSN: 1042-2196.
AU Lees-Miller S P; Anderson C W
AN 92088810 MEDLINE

L49 ANSWER 37 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI MEASUREMENT OF **DNA-ACTIVATED PROTEIN KINASE** ABUNDANCE SYNTHESIS AND ACTIVITY DURING THE CELL-CYCLE.
SO ABSTRACTS OF PAPERS PRESENTED AT THE THIRTY-FIRST ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, BOSTON, MASSACHUSETTS, USA, DECEMBER 8-12, 1991. J CELL BIOL. (1991) 115 (3 PART 2), 283A.
CODEN: JCLBA3. ISSN: 0021-9525.
AU SUN I; CARTER T H
AN 1992:88367 BIOSIS

L49 ANSWER 38 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE 21
TI THE **DNA-ACTIVATED PROTEIN KINASE** **DNA-PK**.
SO JEANTEUR, P., ET AL. (ED.). PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY, VOL. 12. IX+137P. SPRINGER-VERLAG: BERLIN, GERMANY; NEW YORK, NEW YORK, USA. ILLUS. (1991) 0 (0), 37-57.
CODEN: PMSBA4. ISSN: 0079-6484. ISBN: 3-540-53900-X, 0-387-53900-X.
AU CARTER T H; ANDERSON C W
AN 1992:378114 BIOSIS

L49 ANSWER 39 OF 46 MEDLINE DUPLICATE 22
TI Human cells contain a **DNA-activated protein kinase** that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen.
SO MOLECULAR AND CELLULAR BIOLOGY, (1990 Dec) 10 (12) 6472-81.

Journal code: 8109087. ISSN: 0270-7306.
AU Lees-Miller S P; Chen Y R; Anderson C W
AN 91061755 MEDLINE

L49 ANSWER 40 OF 46 MEDLINE DUPLICATE 23
TI **A DNA-activated protein kinase**
from HeLa cell nuclei.
SO MOLECULAR AND CELLULAR BIOLOGY, (1990 Dec) 10 (12) 6460-71.
Journal code: 8109087. ISSN: 0270-7306.
AU Carter T; Vancurova I; Sun I; Lou W; DeLeon S
AN 91061754 MEDLINE

L49 ANSWER 41 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI **A DNA-ACTIVATED PROTEIN-KINASE**
FROM HELA-CELL NUCLEI
SO MOLECULAR AND CELLULAR BIOLOGY, (1990) Vol. 10, No. 12, pp. 6460-6471.
AU CARTER T (Reprint); VANCUROVA I; SUN I; LOU W; DELEON S
AN 90:633085 SCISEARCH

L49 ANSWER 42 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI SV-40 LARGE TUMOR ANTIGEN AND THE TUMOR SUPPRESSOR P53 ARE PHOSPHORYLATED
BY A **DNA-ACTIVATED PROTEIN KINASE**
FROM HUMAN CELLS.
SO EIGHTH INTERNATIONAL CONFERENCE ON METHODS IN PROTEIN SEQUENCE ANALYSIS,
KIRUNA, SWEDEN, JULY 1-6, 1990. J PROTEIN CHEM. (1990) 9 (3), 306-307.
CODEN: JPCHD2. ISSN: 0277-8033.
AU LEES-MILLER S P; CHEN Y-R; ANDERSON C W
AN 1990:484135 BIOSIS

L49 ANSWER 43 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI INTERACTIONS OF THE HUMAN **DNA-ACTIVATED**
PROTEIN KINASE PKD WITH SYNTHETIC ENHANCER
OLIGONUCLEOTIDES.
SO THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, SAN
DIEGO, CALIFORNIA, USA, DECEMBER 9-13, 1990. J CELL BIOL. (1990) 111 (5
PART 2), 134A.
CODEN: JCLBA3. ISSN: 0021-9525.
AU VANCUROVA I; CARTER T H
AN 1991:43905 BIOSIS

L49 ANSWER 44 OF 46 MEDLINE DUPLICATE 24
TI The human double-stranded **DNA-activated**
protein kinase phosphorylates the 90-kDa heat-shock
protein, hsp90 alpha at two NH2-terminal threonine residues.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1989 Oct 15) 264 (29) 17275-80.
Journal code: 2985121R. ISSN: 0021-9258.
AU Lees-Miller S P; Anderson C W
AN 90008887 MEDLINE

L49 ANSWER 45 OF 46 NTIS COPYRIGHT 2003 NTIS
TI PU 3-Kinase: A Pivotal Pathway in T-Cell Activation.
Reprint: PU 3-Kinase: A Pivotal Pathway in T-Cell Activation.
NR AD-A307 005/9/XAB; NMRI-96-04
13p; 1996
AU Ward, S. G.; June, C. H.; Olive, D.
AN 1996(19):06678 NTIS

L49 ANSWER 46 OF 46 NTIS COPYRIGHT 2003 NTIS
TI SV40 large tumor antigen and the tumor suppressor p53 are phosphorylated
by a **DNA-activated protein kinase**
from human cells.
NR DE90016556/XAB; BNL-43799, BIO-4569; CONF-9007160-1
4p; 1990
AU Lees-Miller, S. P.; Chen, Y. R.; Anderson, C. W.

AN 1991(13):02854 NTIS

=> s p53

FILE 'MEDLINE'

L50 28098 P53

FILE 'SCISEARCH'

L51 35120 P53

FILE 'LIFESCI'

L52 9520 P53

FILE 'BIOTECHDS'

L53 1014 P53

FILE 'BIOSIS'

L54 33991 P53

FILE 'EMBASE'

L55 26089 P53

FILE 'HCAPLUS'

L56 23690 P53

FILE 'NTIS'

L57 400 P53

FILE 'ESBIOBASE'

L58 16719 P53

FILE 'BIOTECHNO'

L59 14698 P53

FILE 'WPIDS'

L60 1006 P53

TOTAL FOR ALL FILES

L61 190345 P53

=> s l61(8a)(fragment# or peptide# or portion#)

FILE 'MEDLINE'

202686 FRAGMENT#

328016 PEPTIDE#

85665 PORTION#

L62 519 L50(8A)(FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'SCISEARCH'

153564 FRAGMENT#

238184 PEPTIDE#

72679 PORTION#

L63 568 L51(8A)(FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'LIFESCI'

73702 FRAGMENT#

87272 PEPTIDE#

27722 PORTION#

L64 325 L52(8A)(FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'BIOTECHDS'

38001 FRAGMENT#

23759 PEPTIDE#

8518 PORTION#

L65 75 L53(8A)(FRAGMENT# OR PEPTIDE# OR PORTION#)

```

FILE 'BIOSIS'
    179186 FRAGMENT#
    287886 PEPTIDE#
    101537 PORTION#
L66      612 L54(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'EMBASE'
    138512 FRAGMENT#
    210658 PEPTIDE#
    78707  PORTION#
L67      558 L55(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'HCAPLUS'
    281923 FRAGMENT#
    372530 PEPTIDE#
    281505 PORTION#
L68      793 L56(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'NTIS'
    7808  FRAGMENT#
    3667  PEPTIDE#
    32486 PORTION#
L69      10 L57(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'ESBIOBASE'
    54228 FRAGMENT#
    89705 PEPTIDE#
    24445 PORTION#
L70      394 L58(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'BIOTECHNO'
    95026 FRAGMENT#
    100719 PEPTIDE#
    24349  PORTION#
L71      456 L59(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

FILE 'WPIDS'
    43718 FRAGMENT#
    37856 PEPTIDE#
    950648 PORTION#
L72      93 L60(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

TOTAL FOR ALL FILES
L73      4403 L61(8A) (FRAGMENT# OR PEPTIDE# OR PORTION#)

=> s 173 not 2000-2003/py
FILE 'MEDLINE'
    1724843 2000-2003/PY
L74      361 L62 NOT 2000-2003/PY

FILE 'SCISEARCH'
    3248680 2000-2003/PY
L75      391 L63 NOT 2000-2003/PY

FILE 'LIFESCI'
    326324 2000-2003/PY
L76      241 L64 NOT 2000-2003/PY

FILE 'BIOTECHDS'
    60540 2000-2003/PY
L77      44 L65 NOT 2000-2003/PY

FILE 'BIOSIS'

```

1778159 2000-2003/PY
 L78 423 L66 NOT 2000-2003/PY

 FILE 'EMBASE'
 1483306 2000-2003/PY
 L79 399 L67 NOT 2000-2003/PY

 FILE 'HCAPLUS'
 3283625 2000-2003/PY
 L80 480 L68 NOT 2000-2003/PY

 FILE 'NTIS'
 53037 2000-2003/PY
 L81 7 L69 NOT 2000-2003/PY

 FILE 'ESBIOBASE'
 948733 2000-2003/PY
 L82 255 L70 NOT 2000-2003/PY

 FILE 'BIOTECHNO'
 388989 2000-2003/PY
 L83 338 L71 NOT 2000-2003/PY

 FILE 'WPIDS'
 2930742 2000-2003/PY
 L84 24 L72 NOT 2000-2003/PY

 TOTAL FOR ALL FILES
 L85 2963 L73 NOT 2000-2003/PY

 => s l85 not 1997-1999/py
 FILE 'MEDLINE'
 1333570 1997-1999/PY
 L86 202 L74 NOT 1997-1999/PY

 FILE 'SCISEARCH'
 2862496 1997-1999/PY
 L87 210 L75 NOT 1997-1999/PY

 FILE 'LIFESCI'
 337226 1997-1999/PY
 L88 138 L76 NOT 1997-1999/PY

 FILE 'BIOTECHDS'
 41038 1997-1999/PY
 L89 24 L77 NOT 1997-1999/PY

 FILE 'BIOSIS'
 1680795 1997-1999/PY
 L90 248 L78 NOT 1997-1999/PY

 FILE 'EMBASE'
 1252969 1997-1999/PY
 L91 231 L79 NOT 1997-1999/PY

 FILE 'HCAPLUS'
 2535538 1997-1999/PY
 L92 261 L80 NOT 1997-1999/PY

 FILE 'NTIS'
 85373 1997-1999/PY
 L93 3 L81 NOT 1997-1999/PY

 FILE 'ESBIOBASE'

831730 1997-1999/PY
L94 107 L82 NOT 1997-1999/PY

FILE 'BIOTECHNO'
338670 1997-1999/PY
L95 206 L83 NOT 1997-1999/PY

FILE 'WPIDS'
2351312 1997-1999/PY
L96 3 L84 NOT 1997-1999/PY

TOTAL FOR ALL FILES
L97 1633 L85 NOT 1997-1999/PY

=>
=> s 197 not 1994-1996/py
FILE 'MEDLINE'
1244236 1994-1996/PY
L98 81 L86 NOT 1994-1996/PY

FILE 'SCISEARCH'
2559592 1994-1996/PY
L99 59 L87 NOT 1994-1996/PY

FILE 'LIFESCI'
325401 1994-1996/PY
L100 53 L88 NOT 1994-1996/PY

FILE 'BIOTECHDS'
46905 1994-1996/PY
L101 7 L89 NOT 1994-1996/PY

FILE 'BIOSIS'
1660749 1994-1996/PY
L102 95 L90 NOT 1994-1996/PY

FILE 'EMBASE'
1117373 1994-1996/PY
L103 85 L91 NOT 1994-1996/PY

FILE 'HCAPLUS'
2256014 1994-1996/PY
L104 114 L92 NOT 1994-1996/PY

FILE 'NTIS'
131755 1994-1996/PY
L105 1 L93 NOT 1994-1996/PY

FILE 'ESBIOBASE'
498223 1994-1996/PY
L106 3 L94 NOT 1994-1996/PY

FILE 'BIOTECHNO'
304425 1994-1996/PY
L107 81 L95 NOT 1994-1996/PY

FILE 'WPIDS'
1732428 1994-1996/PY
L108 0 L96 NOT 1994-1996/PY

TOTAL FOR ALL FILES
L109 579 L97 NOT 1994-1996/PY

=> s 1109 and human

```

FILE 'MEDLINE'
      8110736 HUMAN
L110      51 L98 AND HUMAN

FILE 'SCISEARCH'
      1027166 HUMAN
L111      38 L99 AND HUMAN

FILE 'LIFESCI'
      318724 HUMAN
L112      24 L100 AND HUMAN

FILE 'BIOTECHDS'
      54727 HUMAN
L113      4 L101 AND HUMAN

FILE 'BIOSIS'
      5448376 HUMAN
L114      63 L102 AND HUMAN

FILE 'EMBASE'
      4707523 HUMAN
L115      59 L103 AND HUMAN

FILE 'HCAPLUS'
      1135506 HUMAN
L116      74 L104 AND HUMAN

FILE 'NTIS'
      80440 HUMAN
L117      0 L105 AND HUMAN

FILE 'ESBIOBASE'
      350395 HUMAN
L118      2 L106 AND HUMAN

FILE 'BIOTECHNO'
      684986 HUMAN
L119      58 L107 AND HUMAN

FILE 'WPIDS'
      123088 HUMAN
L120      0 L108 AND HUMAN

```

```

TOTAL FOR ALL FILES
L121      373 L109 AND HUMAN

```

```

=> dup rem l121
PROCESSING COMPLETED FOR L121
L122      115 DUP REM L121 (258 DUPLICATES REMOVED)

```

```

=> d tot

```

```

L122 ANSWER 1 OF 115 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
TI   Human protein p53 binding to major histocompatibility complex
      class I molecule;
      cytotoxic T-lymphocyte response in cell culture for application in
      cancer diagnosis and therapy
AN   1994-01949 BIOTECHDS
PI   WO 9324525 9 Dec 1993

L122 ANSWER 2 OF 115 MEDLINE DUPLICATE 1
TI   Analysis of p53 antibodies in patients with various cancers define B-cell
      epitopes of human p53: distribution on primary structure and

```


exposure on protein surface.

SO CANCER RESEARCH, (1993 Dec 15) 53 (24) 5872-6.
Journal code: 2984705R. ISSN: 0008-5472.

AU Lubin R; Schlichtholz B; Bengoufa D; Zalcman G; Tredaniel J; Hirsch A; de Fromentel C C; Preudhomme C; Fenaux P; Fournier G; +

AN 94084640 MEDLINE

L122 ANSWER 3 OF 115 MEDLINE DUPLICATE 2

TI Absence of p53 gene mutations in primary neuroblastomas.

SO CANCER RESEARCH, (1993 Nov 1) 53 (21) 5269-73.
Journal code: 2984705R. ISSN: 0008-5472.

AU Vogan K; Bernstein M; Leclerc J M; Brisson L; Brossard J; Brodeur G M; Pelletier J; Gros P

AN 94036809 MEDLINE

L122 ANSWER 4 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.

SO Cancer Research, (1993) Vol. 53, No. 19, pp. 4469-4473.
ISSN: 0008-5472.

AU Hainaut, Pierre (1); Milner, Jo

AN 1993:525110 BIOSIS

L122 ANSWER 5 OF 115 MEDLINE DUPLICATE 3

TI Mapping of the p53 and mdm-2 interaction domains.

SO MOLECULAR AND CELLULAR BIOLOGY, (1993 Jul) 13 (7) 4107-14.
Journal code: 8109087. ISSN: 0270-7306.

AU Chen J; Marechal V; Levine A J

AN 93309444 MEDLINE

L122 ANSWER 6 OF 115 MEDLINE DUPLICATE 4

TI 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses.

SO NUCLEIC ACIDS RESEARCH, (1993 Aug 11) 21 (16) 3637-42.
Journal code: 0411011. ISSN: 0305-1048.

AU Hongyo T; Buzard G S; Calvert R J; Weghorst C M

AN 93376481 MEDLINE

L122 ANSWER 7 OF 115 MEDLINE DUPLICATE 5

TI A mutant **p53** tumor suppressor protein is a target for **peptide**-induced CD8+ cytotoxic T-cells.

SO CANCER RESEARCH, (1993 Jul 15) 53 (14) 3257-61.
Journal code: 2984705R. ISSN: 0008-5472.

AU Yanuck M; Carbone D P; Pendleton C D; Tsukui T; Winter S F; Minna J D; Berzofsky J A

AN 93313855 MEDLINE

L122 ANSWER 8 OF 115 HCAPLUS COPYRIGHT 2003 ACS

TI Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes

SO EMBO Journal (1993), 12(7), 2799-808
CODEN: EMJODG; ISSN: 0261-4189

AU Zauberman, Arie; Barak, Yaacov; Ragimov, Naomi; Levy, Naomi; Oren, Moshe

AN 1993:488338 HCAPLUS

DN 119:88338

L122 ANSWER 9 OF 115 MEDLINE DUPLICATE 6

TI A proteolytic **fragment** from the central region of **p53** has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.

SO GENES AND DEVELOPMENT, (1993 Dec) 7 (12B) 2565-74.
Journal code: 8711660. ISSN: 0890-9369.

AU Bargonetti J; Manfredi J J; Chen X; Marshak D R; Prives C

AN 94102538 MEDLINE

L122 ANSWER 10 OF 115 MEDLINE DUPLICATE 7
 TI The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
 SO GENES AND DEVELOPMENT, (1993 Dec) 7 (12B) 2556-64.
 Journal code: 8711660. ISSN: 0890-9369.
 AU Pavletich N P; Chambers K A; Pabo C O
 AN 94102537 MEDLINE

L122 ANSWER 11 OF 115 LIFESCI COPYRIGHT 2003 CSA
 TI The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots
 SO GENES DEV., (1993) vol. 7, no. 126, pp. 2556-2564.
 ISSN: 0890-9369.
 AU Pavletich, N.P.; Chambers, K.A.; Pabo, C.O.
 AN 94:27791 LIFESCI

L122 ANSWER 12 OF 115 MEDLINE DUPLICATE 8
 TI Direct interaction between the transcriptional activation domain of **human** p53 and the TATA box-binding protein.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1993 Feb 5) 268 (4) 2284-7.
 Journal code: 2985121R. ISSN: 0021-9258.
 AU Truant R; Xiao H; Ingles C J; Greenblatt J
 AN 93155022 MEDLINE

L122 ANSWER 13 OF 115 MEDLINE DUPLICATE 9
 TI An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1993 Mar 15) 90 (6) 2217-21.
 Journal code: 7505876. ISSN: 0027-8424.
 AU Zhang Q J; Gavioli R; Klein G; Masucci M G
 AN 93211933 MEDLINE

L122 ANSWER 14 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE 10
 TI "Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites.
 SO Clinical Chemistry, (1993) Vol. 39, No. 10, pp. 2186-2191.
 ISSN: 0009-9147.
 AU Chen, Pao-Huei (1); Lin, Shyr-Yi; Wang, Chung-Kwe; Chen, Yi-Jen; Chen, Te-Chuan; Chang, Jan-Gowth
 AN 1993:585486 BIOSIS

L122 ANSWER 15 OF 115 MEDLINE DUPLICATE 11
 TI Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
 SO ONCOGENE, (1993 Aug) 8 (8) 2159-66.
 Journal code: 8711562. ISSN: 0950-9232.
 AU Chen J Y; Funk W D; Wright W E; Shay J W; Minna J D
 AN 93330556 MEDLINE

L122 ANSWER 16 OF 115 MEDLINE DUPLICATE 12
 TI In vitro induction of **human** cytotoxic T lymphocyte responses against **peptides** of mutant and wild-type **p53**.
 SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1993 Sep) 23 (9) 2072-7.
 Journal code: 1273201. ISSN: 0014-2980.
 AU Houbiers J G; Nijman H W; van der Burg S H; Drijfhout J W; Kenemans P; van de Velde C J; Brand A; Momburg F; Kast W M; Melief C J
 AN 93380471 MEDLINE

L122 ANSWER 17 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 13
 TI ALTERATIONS OF THE P53 TUMOR SUPPRESSOR GENE AND ITS ASSOCIATION WITH

ACTIVATION OF THE C-K-RAS-2 PROTOONCOGENE IN PREMALIGNANT AND MALIGNANT
LESIONS OF THE **HUMAN** UTERINE ENDOMETRIUM

SO CANCER RESEARCH, (15 APR 1993) Vol. 53, No. 8, pp. 1883-1888.
ISSN: 0008-5472.
AU ENOMOTO T (Reprint); FUJITA M; INOUE M; RICE J M; NAKAJIMA R; TANIZAWA O;
NOMURA T
AN 93:247083 SCISEARCH

L122 ANSWER 18 OF 115 MEDLINE
TI Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for
transcriptional activation.
SO GENES AND DEVELOPMENT, (1993 Oct) 7 (10) 1837-49.
Journal code: 8711660. ISSN: 0890-9369.
AU Chen X; Farmer G; Zhu H; Prywes R; Prives C
AN 94010283 MEDLINE

L122 ANSWER 19 OF 115 MEDLINE DUPLICATE 14
TI Use of the two-hybrid system to identify the domain of p53 involved in
oligomerization.
SO ONCOGENE, (1993 Jun) 8 (6) 1693-6.
Journal code: 8711562. ISSN: 0950-9232.
AU Iwabuchi K; Li B; Bartel P; Fields S
AN 93275666 MEDLINE

L122 ANSWER 20 OF 115 MEDLINE DUPLICATE 15
TI Pancreatic adenocarcinomas frequently show p53 gene mutations.
SO AMERICAN JOURNAL OF PATHOLOGY, (1993 May) 142 (5) 1534-43.
Journal code: 0370502. ISSN: 0002-9440.
AU Scarpa A; Capelli P; Mukai K; Zamboni G; Oda T; Iacono C; Hirohashi S
AN 93263220 MEDLINE

L122 ANSWER 21 OF 115 MEDLINE DUPLICATE 16
TI State of p53, Rb and DCC tumor suppressor genes in **human** oral
cancer cell lines.
SO ANTICANCER RESEARCH, (1993 Sep-Oct) 13 (5A) 1405-13.
Journal code: 8102988. ISSN: 0250-7005.
AU Kim M S; Li S L; Bertolami C N; Cherrick H M; Park N H
AN 94058082 MEDLINE

L122 ANSWER 22 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 17
TI HIGH-LEVELS OF P53 PROTEIN EXPRESSION DO NOT CORRELATE WITH P53
GENE-MUTATIONS IN ANAPLASTIC LARGE-CELL LYMPHOMA
SO AMERICAN JOURNAL OF PATHOLOGY, (SEP 1993) Vol. 143, No. 3, pp. 845-856.
ISSN: 0002-9440.
AU CESARMAN E; INGHIRAMI G; CHADBURN A; KNOWLES D M (Reprint)
AN 93:570858 SCISEARCH

L122 ANSWER 23 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI WAF1, a potential mediator of p53 tumor suppression
SO Cell (Cambridge, MA, United States) (1993), 75(4), 817-25
CODEN: CELLB5; ISSN: 0092-8674
AU El-Deiry, Wafik S.; Tokino, Takashi; Velculescu, Victor E.; Levy, Daniel
B.; Parsons, Ramon; Trent, Jeffrey M.; Lin, David; Mercer, W. Edward;
Kinzler, Kenneth W.; Vogelstein, Bert
AN 1994:97539 HCAPLUS
DN 120:97539

L122 ANSWER 24 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Release of the p53-induced repression on thymidine kinase promoter by
single p53-binding sequence
SO Biochemical and Biophysical Research Communications (1993), 191(2), 662-8
CODEN: BBRC99; ISSN: 0006-291X
AU Yuan, Jean Nian; Liu, Biing Hui; Lee, Heng; Shaw, Yueh Tsern; Chiou, Shean
Tai; Chang, Wen Chang; Lai, Ming Derg

AN 1993:227382 HCAPLUS
DN 118:227382

L122 ANSWER 25 OF 115 MEDLINE DUPLICATE 18
TI Lack of allelic deletion and point mutation as mechanisms of p53
activation in **human** malignant melanoma.
SO INTERNATIONAL JOURNAL OF CANCER, (1993 Oct 21) 55 (4) 562-5.
Journal code: 0042124. ISSN: 0020-7136.
AU Castresana J S; Rubio M P; Vazquez J J; Idoate M; Sober A J; Seizinger B
R; Barnhill R L
AN 94011506 MEDLINE

L122 ANSWER 26 OF 115 MEDLINE DUPLICATE 19
TI Current topics of immunohistochemistry as applied to skin tumors.
SO JOURNAL OF DERMATOLOGY, (1993 Sep) 20 (9) 521-32. Ref: 61
Journal code: 7600545. ISSN: 0385-2407.
AU Hashimoto K; Fujiwara K; Mehregan A
AN 94044149 MEDLINE

L122 ANSWER 27 OF 115 MEDLINE DUPLICATE 20
TI Molecular genetics of pediatric brain stem gliomas. Application of PCR
techniques to small and archival brain tumor specimens.
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, (1993 Sep) 52 (5)
507-15.
Journal code: 2985192R. ISSN: 0022-3069.
AU Louis D N; Rubio M P; Correa K M; Gusella J F; von Deimling A
AN 93367522 MEDLINE

L122 ANSWER 28 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Endogenous **p53** tumor suppressor protein is a target for
peptide-induced CD8 positive cytotoxic T cells.
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (1993) Vol. 34, No. 0, pp. 491.
Meeting Info.: 84th Annual Meeting of the American Association for Cancer
Research Orlando, Florida, USA May 19-22, 1993
ISSN: 0197-016X.
AU Carbone, David P. (1); Yanuck, Michael; Pendleton, C. David; Tsukui, Taku;
Winter, Stefan; Minna, John D. (1); Berzofsky, Jay A.
AN 1993:400810 BIOSIS

L122 ANSWER 29 OF 115 MEDLINE DUPLICATE 21
TI p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma
from Japan.
SO CANCER, (1993 Jul 15) 72 (2) 355-60.
Journal code: 0374236. ISSN: 0008-543X.
AU Nose H; Imazeki F; Ohto M; Omata M
AN 93306576 MEDLINE

L122 ANSWER 30 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Expression of **human** p53 gene as glutathione S-transferase fusion
proteins in Escherichia coli
SO Misaengmul Hakhoechi (1993), 31(4), 279-85
CODEN: MIHCAR; ISSN: 0440-2413
AU Oh, Sang Jin
AN 1994:185610 HCAPLUS
DN 120:185610

L122 ANSWER 31 OF 115 MEDLINE DUPLICATE 22
TI Alternative splicing of the p53 tumor suppressor gene in the Molt-4
T-lymphoblastic leukemia cell line.
SO CANCER LETTERS, (1993 Sep 30) 73 (2-3) 141-8.
Journal code: 7600053. ISSN: 0304-3835.
AU Chow V T; Quek H H; Tock E P
AN 94036762 MEDLINE

L122 ANSWER 32 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI Can **p53 peptides** serve as tumor-specific antigens?
 SO Pept. 1992, Proc. Eur. Pept. Symp., 22nd (1993), Meeting Date 1992, 136-8.
 Editor(s): Schneider, Conrad H.; Eberle, Alex N. Publisher: ESCOM, Leiden,
 Neth.
 CODEN: 60LUAN
 AU Leder, Gerhard H.; Storkus, Walter J.; Zeh, Herbert J.; Lotze, Michael T.
 AN 1995:66924 HCAPLUS
 DN 122:78596

L122 ANSWER 33 OF 115 MEDLINE DUPLICATE 23
 TI Characterization of cytotoxic T lymphocyte epitopes of a self-protein,
 p53, and a non-self-protein, influenza matrix: relationship between major
 histocompatibility complex peptide binding affinity and immune
 responsiveness to peptides.
 SO JOURNAL OF IMMUNOTHERAPY, (1993 Aug) 14 (2) 121-6.
 Journal code: 9102704. ISSN: 1053-8550.
 AU Nijman H W; Houbiers J G; van der Burg S H; Vierboom M P; Kenemans P; Kast
 W M; Melief C J
 AN 94107850 MEDLINE

L122 ANSWER 34 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 TI A mutant **p53** tumor suppressor protein is a target for
peptide-induced CD8-positive cytotoxic.
 SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART D,
 pp. 113.
 Meeting Info.: Keystone Symposium on Cellular Immunity and the
 Immunotherapy of Cancer Taos, New Mexico, USA March 17-24, 1993
 ISSN: 0733-1959.
 AU Yanuck, Michael (1); Carbone, David; Pendleton, C. David (1); Tsukui, Taku
 (1); Minna, John D.; Berzofsky, Jay A. (1)
 AN 1993:309486 BIOSIS

L122 ANSWER 35 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 TI **P53 peptides** reconstitute HLA-A2 expression and confer
 susceptibility to TIL-lysis.
 SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART D,
 pp. 109.
 Meeting Info.: Keystone Symposium on Cellular Immunity and the
 Immunotherapy of Cancer Taos, New Mexico, USA March 17-24, 1993
 ISSN: 0733-1959.
 AU Leder, Gerhard H. (1); Storkus, Walter J. (1); Stuber, Gyorgy; Modrow,
 Susanne; Lotze, Michael T. (1)
 AN 1993:309471 BIOSIS

L122 ANSWER 36 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 TI In vitro induction of primary CTL response against wild type or mutant
p53 peptides.
 SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART D,
 pp. 109.
 Meeting Info.: Keystone Symposium on Cellular Immunity and the
 Immunotherapy of Cancer Taos, New Mexico, USA March 17-24, 1993
 ISSN: 0733-1959.
 AU Houbiers, Jos G. A. (1); Nijman, H. W. (1); V D Burg, S. H. (1);
 Drijfhout, J. W. (1); Kenemans, P.; V D Velde, C. H. J.; Brand, A. (1);
 Kast, W. M. (1); Melief, C. J. M. (1)
 AN 1993:309470 BIOSIS

L122 ANSWER 37 OF 115 MEDLINE DUPLICATE 24
 TI HLA class I binding of synthetic nonamer peptides carrying major anchor
 residue motifs of HLA-B27 (B*2705)-binding peptides.
 SO IMMUNOGENETICS, (1993) 38 (1) 41-6.
 Journal code: 0420404. ISSN: 0093-7711.

AU Fruci D; Rovero P; Butler R H; Sorrentino R; Tosi R; Tanigaki N
AN 93216306 MEDLINE

L122 ANSWER 38 OF 115 MEDLINE DUPLICATE 25
TI Comparative study of p53 gene and protein alterations in **human** astrocytic tumors.
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, (1993 Jan) 52 (1) 31-8.
Journal code: 2985192R. ISSN: 0022-3069.
AU Louis D N; von Deimling A; Chung R Y; Rubio M P; Whaley J M; Eibl R H; Ohgaki H; Wiestler O D; Thor A D; Seizinger B R
AN 93147838 MEDLINE

L122 ANSWER 39 OF 115 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 26
TI Screening of point mutations of p53 gene in primary lung cancer using single-strand conformation polymorphism analysis of polymerase chain reaction.
SO Japanese Journal of Lung Cancer, (1993) 33/1 (19-28).
ISSN: 0386-9628 CODEN: HGANAO
AU Matsuda K.; Takahashi H.; Seyama K.; Nukiwa T.
AN 93130460 EMBASE

L122 ANSWER 40 OF 115 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
TI Cloned p53 cDNA and protein;
tumor suppressor protein DNA sequence application in osteosarcoma, leukemia, lymphoma, etc., tumor gene therapy
AN 1992-06679 BIOTECHDS
PI EP 475623 18 Mar 1992

L122 ANSWER 41 OF 115 MEDLINE DUPLICATE 27
TI Plateau distributions of DNA fragment lengths produced by extended light exposure of extranuclear photosensitizers in **human** cells.
SO NUCLEIC ACIDS RESEARCH, (1992 Dec 25) 20 (24) 6687-93.
Journal code: 0411011. ISSN: 0305-1048.
AU Kvam E; Stokke T; Moan J; Steen H B
AN 93126113 MEDLINE

L122 ANSWER 42 OF 115 MEDLINE DUPLICATE 28
TI p53 mutations in formaldehyde-induced nasal squamous cell carcinomas in rats.
SO CANCER RESEARCH, (1992 Nov 1) 52 (21) 6113-6.
Journal code: 2984705R. ISSN: 0008-5472.
AU Recio L; Sisk S; Pluta L; Bermudez E; Gross E A; Chen Z; Morgan K; Walker C
AN 93008019 MEDLINE

L122 ANSWER 43 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding.
SO Molecular and Cellular Biology, (1992) Vol. 12, No. 12, pp. 5581-5592.
ISSN: 0270-7306.
AU Shaulian, Eitan; Zauberman, Arie; Ginsberg, Doron; Oren, Moshe (1)
AN 1993:76251 BIOSIS

L122 ANSWER 44 OF 115 MEDLINE DUPLICATE 29
TI **Human** DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of **human** p53.
SO MOLECULAR AND CELLULAR BIOLOGY, (1992 Nov) 12 (11) 5041-9.
Journal code: 8109087. ISSN: 0270-7306.
AU Lees-Miller S P; Sakaguchi K; Ullrich S J; Appella E; Anderson C W
AN 93024450 MEDLINE

L122 ANSWER 45 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 30
TI RAT P53 GENE-MUTATIONS IN PRIMARY ZYMBALE GLAND TUMORS INDUCED BY

2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE, A FOOD MUTAGEN
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (01 JUN 1992) Vol. 89, No. 11, pp. 4850-4854.
ISSN: 0027-8424.
AU MAKINO H; ISHIZAKA Y; TSUJIMOTO A; NAKAMURA T; ONDA M; SUGIMURA T; NAGAO M (Reprint)
AN 92:348681 SCISEARCH

L122 ANSWER 46 OF 115 LIFESCI COPYRIGHT 2003 CSA
TI Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-3-methylimidazo(4,5-f)quinoline, a food mutagen.
SO PROC. NATL. ACAD. SCI. USA., (1992) vol. 89, no. 11, pp. 4850-4854.
AU Makino, H.; Ishizaka, Y.; Tsujimoto, A.; Nakamura, T.; Onda, M.; Sugimura, T.; Nagao, M.
AN 92:18430 LIFESCI

L122 ANSWER 47 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 31
TI INDUCTION OF APOPTOSIS BY WILD-TYPE P53 IN A **HUMAN** COLON TUMOR-DERIVED CELL-LINE
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (15 MAY 1992) Vol. 89, No. 10, pp. 4495-4499.
ISSN: 0027-8424.
AU SHAW P (Reprint); BOVEY R; TARDY S; SAHLI R; SORDAT B; COSTA J
AN 92:319483 SCISEARCH

L122 ANSWER 48 OF 115 LIFESCI COPYRIGHT 2003 CSA
TI Induction of apoptosis by wild-type p53 in a **human** colon tumor-derived cell line.
SO PROC. NATL. ACAD. SCI. USA., (1992) vol. 89, no. 10, pp. 4495-4499.
AU Shaw, P.; Bovey, R.; Tardy, S.; Sahli, R.; Sordat, B.; Costa, J.
AN 92:19168 LIFESCI

L122 ANSWER 49 OF 115 MEDLINE DUPLICATE 32
TI EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein.
SO JOURNAL OF IMMUNOLOGY, (1992 Nov 15) 149 (10) 3232-8.
Journal code: 2985117R. ISSN: 0022-1767.
AU Frade R; Gauffre A; Hermann J; Barel M
AN 93056484 MEDLINE

L122 ANSWER 50 OF 115 MEDLINE DUPLICATE 33
TI Phosphorylation-associated conformation shift of anti-oncogene phosphoprotein p53 in concanavalin-A activated **human** T lymphocytes.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1992 Dec 30) 189 (3) 1701-8.
Journal code: 0372516. ISSN: 0006-291X.
AU McClure J E; McClure J A; Shearer W T
AN 93129247 MEDLINE

L122 ANSWER 51 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI PCR detection of a BglII polymorphism in intron 1 of the **human** p53 gene (TP53)
SO Nucleic Acids Research (1992), 20(5), 1172
CODEN: NARHAD; ISSN: 0305-1048
AU Willems, P. M. W.; Meyerink, J. P. P.; Van de Locht, L. T. F.; Smetsers, T. F. C. M.; De Vries, N.; Mensink, E. J. B. M.
AN 1992:229382 HCAPLUS
DN 116:229382

L122 ANSWER 52 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI A new TaqI polymorphism in the p53 gene
SO Nucleic Acids Research (1992), 20(4), 928

CODEN: NARHAD; ISSN: 0305-1048

AU Serra, A.; Gaidano, G. L.; Revello, D.; Guerrasio, A.; Ballerini, P.;
Dalla Favera, R.; Saglio, G.
AN 1992:208931 HCAPLUS
DN 116:208931

L122 ANSWER 53 OF 115 MEDLINE DUPLICATE 34
TI p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during
human astrocytoma progression.
SO CANCER RESEARCH, (1992 Feb 1) 52 (3) 674-9.
Journal code: 2984705R. ISSN: 0008-5472.
AU Fults D; Brockmeyer D; Tullous M W; Pedone C A; Cawthon R M
AN 92119628 MEDLINE

L122 ANSWER 54 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Expression of p53 gene in B-cell peripheral lymphocytes
SO Bollettino - Societa Italiana di Biologia Sperimentale (1992), 68(10),
597-600
CODEN: BSIBAC; ISSN: 0037-8771
AU Gandini, D.; Moretti, S.; Latorraca, A.; Lanza, F.; del Senno, L.
AN 1993:442617 HCAPLUS
DN 119:42617

L122 ANSWER 55 OF 115 MEDLINE DUPLICATE 35
TI The rat genome contains a p53 pseudogene: detection of a processed
pseudogene using PCR.
SO PCR METHODS AND APPLICATIONS, (1992 May) 1 (4) 251-4.
Journal code: 9201445. ISSN: 1054-9803.
AU Hulla J E
AN 93121053 MEDLINE

L122 ANSWER 56 OF 115 MEDLINE DUPLICATE 36
TI An immunochemical analysis of the **human** nuclear phosphoprotein
p53. New monoclonal antibodies and epitope mapping using recombinant p53.
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1992 Jul 6) 151 (1-2) 237-44.
Journal code: 1305440. ISSN: 0022-1759.
AU Vojtesek B; Bartek J; Midgley C A; Lane D P
AN 92333109 MEDLINE

L122 ANSWER 57 OF 115 MEDLINE
TI hsp70 binds specifically to a peptide derived from the highly conserved
domain (I) region of p53.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1992 Apr 15) 184 (1)
167-74.
Journal code: 0372516. ISSN: 0006-291X.
AU Lam K T; Calderwood S K
AN 92231922 MEDLINE

L122 ANSWER 58 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI ALTERATIONS IN THE STRUCTURAL GENE AND THE EXPRESSION OF P53 IN RAT-LIVER
TUMORS INDUCED BY AFLATOXIN-B(1)
SO MOLECULAR CARCINOGENESIS, (1992) Vol. 6, No. 2, pp. 159-172.
ISSN: 0899-1987.
AU LILLEBERG S L; CABONCE M A; RAJU N R; WAGNER L M; KIER L D (Reprint)
AN 92:575008 SCISEARCH

L122 ANSWER 59 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Characterization of the interactions of a bifunctional inhibitor with
.alpha.-thrombin by molecular modeling and peptide synthesis
SO Protein Engineering (1992), 5(1), 77-85
CODEN: PRENE9; ISSN: 0269-2139
AU Yue, S. Y.; DiMaio, J.; Szewczuk, Z.; Purisima, E. O.; Ni, F.; Konishi, Y.
AN 1992:187498 HCAPLUS
DN 116:187498

L122 ANSWER 60 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI BstNI/NciI polymorphism of the **human** p53 gene (TP53)
 SO Nucleic Acids Research (1991), 19(24), 6969
 CODEN: NARHAD; ISSN: 0305-1048
 AU Chumakov, P. M.; Jenkins, J. R.
 AN 1992:52757 HCAPLUS
 DN 116:52757

L122 ANSWER 61 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI p53 Gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases
 SO Cancer Research (1991), 51(21), 5800-5
 CODEN: CNREA8; ISSN: 0008-5472
 AU Yamada, Yukishige; Yoshida, Teruhiko; Hayashi, Kenshi; Sekiya, Takao; Yokota, Jun; Hirohashi, Setsuo; Nakatani, Katsunori; Nakano, Hiroshige; Sugimura, Takashi; Terada, Masaaki
 AN 1991:672340 HCAPLUS
 DN 115:272340

L122 ANSWER 62 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 37
 TI GENETIC ALTERATIONS OF THE P53 GENE ARE A FEATURE OF MALIGNANT MESOTHELIOMAS
 SO CANCER RESEARCH, (1991) Vol. 51, No. 19, pp. 5410-5416.
 AU COTE R J (Reprint); JHANWAR S C; NOVICK S; PELLICER A
 AN 91:546611 SCISEARCH

L122 ANSWER 63 OF 115 LIFESCI COPYRIGHT 2003 CSA DUPLICATE 38
 TI Frequent allelic losses and mutations of the p53 gene in **human** ovarian cancer.
 SO CANCER RES., (1991) vol. 51, no. 19, pp. 5171-5176.
 AU Okamoto, A.; Sameshima, Y.; Yokoyama, S.; Terashima, Y.; Sugimura, T.; Terada, M.; Yokota, J.
 AN 91:55861 LIFESCI

L122 ANSWER 64 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISI
 TI FREQUENT ALLELIC LOSSES AND MUTATIONS OF THE P53 GENE IN **HUMAN** OVARIAN-CANCER
 SO CANCER RESEARCH, (1991) Vol. 51, No. 19, pp. 5171-5176.
 AU OKAMOTO A; SAMESHIMA Y; YOKOYAMA S; TERASHIMA Y; SUGIMURA T; TERADA M; YOKOTA J (Reprint)
 AN 91:546575 SCISEARCH

L122 ANSWER 65 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI Biallelic ApaI polymorphism of the **human** p53 gene (TP53)
 SO Nucleic Acids Research (1991), 19(17), 4799
 CODEN: NARHAD; ISSN: 0305-1048
 AU Prosser, Jane; Condie, Alison
 AN 1991:649327 HCAPLUS
 DN 115:249327

L122 ANSWER 66 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products
 SO Nucleic Acids Research (1991), 19(17), 4796
 CODEN: NARHAD; ISSN: 0305-1048
 AU McDaniel, Tim; Carbone, David; Takahashi, Takashi; Chumakov, Peter; Chang, Esther H.; Pirolo, Kathleen F.; Yin, Jing; Huang, Ying; Meltzer, Stephen J.
 AN 1991:600203 HCAPLUS
 DN 115:200203

L122 ANSWER 67 OF 115 MEDLINE DUPLICATE 39
 TI Loss of heterozygosity of p53 gene and p53 protein expression in

human colorectal carcinomas.

SO CANCER RESEARCH, (1991 Aug 15) 51 (16) 4436-42.
Journal code: 2984705R. ISSN: 0008-5472.

AU Campo E; de la Calle-Martin O; Miquel R; Palacin A; Romero M; Fabregat V;
Vives J; Cardesa A; Yague J

AN 91330165 MEDLINE

L122 ANSWER 68 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISI

TI LOSS OF HETEROZYGOSITY OF P53-GENE AND P53-PROTEIN EXPRESSION IN
HUMAN COLORECTAL CARCINOMAS

SO CANCER RESEARCH, (1991) Vol. 51, No. 16, pp. 4436-4442.

AU CAMPO E (Reprint); DELACALLEMARTIN O; MIQUEL R; PALACIN A; ROMERO M;
FABREGAT V; VIVES J; CARDESA A; YAGUE J

AN 91:454935 SCISEARCH

L122 ANSWER 69 OF 115 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI

TI Protocols for an improved detection of point mutations by SSCP;
optimization of point mutation detection by single strand conformation
polymorphism

SO Nucleic Acids Res.; (1991) 19, 14, 4009
CODEN: NARHAD

AU Spinardi L; Mazars R; Theillet C

AN 1991-10876 BIOTECHDS

L122 ANSWER 70 OF 115 MEDLINE DUPLICATE 41

TI Mutations in the p53 gene in myelodysplastic syndromes.

SO ONCOGENE, (1991 Dec) 6 (12) 2243-7.
Journal code: 8711562. ISSN: 0950-9232.

AU Jonveaux P; Fenaux P; Quiquandon I; Pignon J M; Lai J L; Loucheux-Lefebvre
M H; Goossens M; Bauters F; Berger R

AN 92115324 MEDLINE

L122 ANSWER 71 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 42

TI P53 MUTATIONS IN OVARIAN-CANCER - A LATE EVENT

SO ONCOGENE, (SEP 1991) Vol. 6, No. 9, pp. 1685-1690.
ISSN: 0950-9232.

AU MAZARS R; PUJOL P; MAUDELONDE T; JEANTEUR P; THEILLET C (Reprint)

AN 92:16971 SCISEARCH

L122 ANSWER 72 OF 115 MEDLINE DUPLICATE 43

TI Association of casein kinase II with immunopurified p53.

SO ONCOGENE, (1991 May) 6 (5) 877-84.
Journal code: 8711562. ISSN: 0950-9232.

AU Herrmann C P; Kraiss S; Montenarh M

AN 91270909 MEDLINE

L122 ANSWER 73 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 44

TI CHARACTERIZATION OF SYNTHETIC PEPTIDE-SUBSTRATES FOR P34CDC2
PROTEIN-KINASE

SO JOURNAL OF CELLULAR BIOCHEMISTRY, (1991) Vol. 45, No. 4, pp. 391-400.

AU MARSHAK D R (Reprint); VANDENBERG M T; BAE Y S; YU I J

AN 91:232391 SCISEARCH

L122 ANSWER 74 OF 115 MEDLINE DUPLICATE 45

TI Detection of loss of heterozygosity in tumor DNA samples by PCR.

SO BIOTECHNIQUES, (1991 Aug) 11 (2) 166-8, 170-1.
Journal code: 8306785. ISSN: 0736-6205.

AU Merlo G R; Cropp C S; Callahan R; Takahashi T

AN 92030094 MEDLINE

L122 ANSWER 75 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISI

TI DETECTION OF LOSS OF HETEROZYGOSITY IN TUMOR DNA SAMPLES BY PCR

SO BIOTECHNIQUES, (1991) Vol. 11, No. 2, pp. 166.

AU MERLO G R; CROPP C S; CALLAHAN R (Reprint); TAKAHASHI T

AN 91:475358 SCISEARCH

L122 ANSWER 76 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI INVESTIGATION OF ALLELE LOSS AT 17P13 LOCI YNZ22 AND P53 GENE IN PRIMARY
BREAST CANCER BY PCR-RFLP TECHNIQUES AND ITS RELATION TO P53
OVEREXPRESSION AND DISEASE OUTCOME.
SO ELEVENTH BIENNIAL MEETING OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH,
GENOA, ITALY, NOVEMBER 3-6, 1991. EUR J CANCER. (1991) 27 (SUPPL 3), S69.
CODEN: EJCAEL. ISSN: 0959-8049.
AU SINGH S; SIMON M; MEYBOHM I; JONAT W; MAASS H; GOEDDE H
AN 1992:61302 BIOSIS

L122 ANSWER 77 OF 115 MEDLINE DUPLICATE 46
TI Frequent mutation of the p53 gene in **human** esophageal cancer.
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA, (1990 Dec) 87 (24) 9958-61.
Journal code: 7505876. ISSN: 0027-8424.
AU Hollstein M C; Metcalf R A; Welsh J A; Montesano R; Harris C C
AN 91088630 MEDLINE

L122 ANSWER 78 OF 115 MEDLINE DUPLICATE 47
TI p53 gene mutations occur in combination with 17p allelic deletions as late
events in colorectal tumorigenesis.
SO CANCER RESEARCH, (1990 Dec 1) 50 (23) 7717-22.
Journal code: 2984705R. ISSN: 0008-5472.
AU Baker S J; Preisinger A C; Jessup J M; Paraskeva C; Markowitz S; Willson J
K; Hamilton S; Vogelstein B
AN 91070526 MEDLINE

L122 ANSWER 79 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI MspI polymorphism of the **human** p53 gene
SO Nucleic Acids Research (1990), 18(16), 4963
CODEN: NARHAD; ISSN: 0305-1048
AU De la Calle-Martin, Oscar; Romero, Matilde; Fabregat, Virginia; Ercilla,
Guadalupe; Vives, Jordi; Yague, Jordi
AN 1990:605898 HCAPLUS
DN 113:205898

L122 ANSWER 80 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI AccII polymorphism of the p53 gene
SO Nucleic Acids Research (1990), 18(16), 4963
CODEN: NARHAD; ISSN: 0305-1048
AU De la Calle-Martin, Oscar; Fabregat, Virginia; Romero, Matilde; Soler,
Jesus; Vives, Jordi; Yague, Jordi
AN 1990:566707 HCAPLUS
DN 113:166707

L122 ANSWER 81 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Codon 72 polymorphism of the TP53 gene
SO Nucleic Acids Research (1990), 18(16), 4961
CODEN: NARHAD; ISSN: 0305-1048
AU Ara, S.; Lee, P. S. Y.; Hansen, M. F.; Saya, H.
AN 1990:566703 HCAPLUS
DN 113:166703

L122 ANSWER 82 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 48
TI A POTENTIAL TRANSCRIPTIONAL ACTIVATION ELEMENT IN THE P53-PROTEIN
SO ONCOGENE, (1990) Vol. 5, No. 12, pp. 1829-1832.
AU OROURKE R W; MILLER C W; KATO G J; SIMON K J; CHEN D L; DANG C V; KOEFFLER
H P (Reprint)
AN 91:47631 SCISEARCH

L122 ANSWER 83 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Variation in the protein coding region of the **human** p53 gene

SO Oncogene (1990), 5(9), 1409-10
 CODEN: ONCNES; ISSN: 0950-9232
 AU Ahuja, H. G.; Testa, M. P.; Cline, M. J.
 AN 1991:1552 HCAPLUS
 DN 114:1552

L122 ANSWER 84 OF 115 MEDLINE DUPLICATE 49
 TI Presence of a potent transcription activating sequence in the p53 protein.
 SO SCIENCE, (1990 Aug 31) 249 (4972) 1046-9.
 Journal code: 0404511. ISSN: 0036-8075.
 AU Fields S; Jang S K
 AN 90371302 MEDLINE

L122 ANSWER 85 OF 115 MEDLINE DUPLICATE 50
 TI BglIII restriction **fragment** length polymorphisms at the
human p53 gene locus.
 SO HUMAN GENETICS, (1990 Dec) 86 (2) 244.
 Journal code: 7613873. ISSN: 0340-6717.
 AU Masharani U; Wolf D
 AN 91092644 MEDLINE

L122 ANSWER 86 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISI
 TI BGLII RESTRICTION-**FRAGMENT**-LENGTH-POLYMORPHISMS AT THE
HUMAN P53 GENE LOCUS
 SO HUMAN GENETICS, (1990) Vol. 86, No. 2, pp. 244.
 AU MASHARANI U (Reprint); WOLF D
 AN 91:6128 SCISEARCH

L122 ANSWER 87 OF 115 MEDLINE DUPLICATE 51
 TI Partial transformation of **human** tumor cell lines showing
 defective interaction between unusual p53 gene product and SV40 large-T
 antigen.
 SO ONCOGENE, (1990 Feb) 5 (2) 207-18.
 Journal code: 8711562. ISSN: 0950-9232.
 AU Van Roy F; Liebaut G; Mareel M; Fiers W
 AN 90206623 MEDLINE

L122 ANSWER 88 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI Biallelic Bgl II DNA polymorphism of the **human** p53 oncogene
 SO Nucleic Acids Research (1990), 18(1), 206
 CODEN: NARHAD; ISSN: 0305-1048
 AU De la Calle, Oscar; Yague, Jordi; Gaya, Antoni; Romero, Matilde; Vives,
 Jordi
 AN 1990:93113 HCAPLUS
 DN 112:93113

L122 ANSWER 89 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53,
 HSP70, and HIV tat proteins
 SO Journal of Biological Chemistry (1989), 264(30), 18019-23
 CODEN: JBCHA3; ISSN: 0021-9258
 AU Dang, Chi V.; Lee, William M. F.
 AN 1990:32202 HCAPLUS
 DN 112:32202

L122 ANSWER 90 OF 115 MEDLINE DUPLICATE 52
 TI Epstein-Barr virus/complement **fragment** C3d receptor (CR2) reacts
 with **p53**, a cellular antioncogene-encoded membrane
 phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2
 antibodies.
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
 AMERICA, (1989 Dec) 86 (24) 10054-8.
 Journal code: 7505876. ISSN: 0027-8424.
 AU Barel M; Fiandino A; Lyamani F; Frade R

AN 90099295 MEDLINE

L122 ANSWER 91 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI A BamHI-polymorphism is detected by a genomic p53-clone (pBHP53)
SO Nucleic Acids Research (1989), 17(21), 8898
CODEN: NARHAD; ISSN: 0305-1048
AU Hoyheim, B.; Nakamura, Y.; White, R.
AN 1990:17216 HCAPLUS
DN 112:17216

L122 ANSWER 92 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI HIGH INCIDENCE OF LUNG BONE AND LYMPHOID TUMORS IN TRANSGENIC MICE
OVEREXPRESSING MUTANT ALLELES OF THE P53 ONCOGENE.
SO MOL CELL BIOL, (1989) 9 (9), 3982-3991.
CODEN: MCEBD4. ISSN: 0270-7306.
AU LAVIGUEUR A; MALTBY V; MOCK D; ROSSANT J; PAWSON T; BERNSTEIN A
AN 1989:474257 BIOSIS

L122 ANSWER 93 OF 115 MEDLINE DUPLICATE 53
TI Two promoters that map to 5'-sequences of the **human** p53 gene are
differentially regulated during terminal differentiation of **human**
myeloid leukemic cells.
SO ONCOGENE, (1989 Aug) 4 (8) 945-53.
Journal code: 8711562. ISSN: 0950-9232.
AU Reisman D; Rotter V
AN 89344874 MEDLINE

L122 ANSWER 94 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein
SO Nucleic Acids Research (1988), 16(23), 11384
CODEN: NARHAD; ISSN: 0305-1048
AU Soussi, Thierry; Caron de Fromentel, Claude; Breugnot, Claude; May,
Evelyne
AN 1989:472223 HCAPLUS
DN 111:72223

L122 ANSWER 95 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein
SO Nucleic Acids Research (1988), 16(23), 11383
CODEN: NARHAD; ISSN: 0305-1048
AU Soussi, Thierry; Begue, Agnes; Kress, Michel; Stehelin, Dominique; May,
Pierre
AN 1989:472222 HCAPLUS
DN 111:72222

L122 ANSWER 96 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI BanII and ScaI RFLPs at the **human** p53 gene locus
SO Nucleic Acids Research (1988), 16(15), 7757
CODEN: NARHAD; ISSN: 0305-1048
AU Masharani, Umesh; Wolf, David; Frossard, Philippe M.
AN 1988:523667 HCAPLUS
DN 109:123667

L122 ANSWER 97 OF 115 MEDLINE DUPLICATE 54
TI **Human** p53 oncogene contains one promoter upstream of exon 1 and
a second, stronger promoter within intron 1.
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA, (1988 Jul) 85 (14) 5146-50.
Journal code: 7505876. ISSN: 0027-8424.
AU Reisman D; Greenberg M; Rotter V
AN 88276914 MEDLINE

L122 ANSWER 98 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
DUPLICATE 55

TI STRUCTURAL ANALYSIS OF A HEPATITIS B VIRUS GENOME INTEGRATED INTO
CHROMOSOME 17P OF A **HUMAN** HEPATOCELLULAR CARCINOMA.
SO J VIROL, (1988) 62 (11), 4224-4231.
CODEN: JOVIAM. ISSN: 0022-538X.
AU ZHOU Y-Z; SLAGLE B L; DONEHOWER L A; VANTUINEN P; LEDBETTER D H; BUTEL J S
AN 1989:6863 BIOSIS

L122 ANSWER 99 OF 115 MEDLINE DUPLICATE 56
TI Fine specificity of murine class II-restricted T cell clones for synthetic
peptides of influenza virus hemagglutinin. Heterogeneity of antigen
interaction with the T cell and the Ia molecule.
SO JOURNAL OF IMMUNOLOGY, (1988 Jun 15) 140 (12) 4083-90.
Journal code: 2985117R. ISSN: 0022-1767.
AU Mills K H; Burt D S; Skehel J J; Thomas D B
AN 88229111 MEDLINE

L122 ANSWER 100 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Bacterial expression of **human** p53 oncogene in the form of a
fused protein
SO Doklady Akademii Nauk SSSR (1988), 302(6), 1501-3, 1 plate [Biochem.]
CODEN: DANKAS; ISSN: 0002-3264
AU Maimets, T. O.
AN 1989:568587 HCAPLUS
DN 111:168587

L122 ANSWER 101 OF 115 MEDLINE DUPLICATE 57
TI A novel 53 kDa protein complexed with P210bcr-abl in **human**
chronic myelogenous leukemia cells.
SO ONCOGENE, (1988 Jun) 2 (6) 559-66.
Journal code: 8711562. ISSN: 0950-9232.
AU Li W J; Kloetzer W S; Arlinghaus R B
AN 88262248 MEDLINE

L122 ANSWER 102 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI A variation in the structure of the protein-coding region of the
human p53 gene
SO Gene (1988), 70(2), 245-52
CODEN: GENED6; ISSN: 0378-1119
AU Bushman, V. L.; Chumakov, P. M.; Ninkina, N. N.; Samarina, O. P.;
Georgiev, G. P.
AN 1989:472174 HCAPLUS
DN 111:72174

L122 ANSWER 103 OF 115 MEDLINE DUPLICATE 58
TI Expression of the cellular p53 protein in cells transformed by adenovirus
12 and viral DNA fragments.
SO VIROLOGY, (1988 Mar) 163 (1) 201-4.
Journal code: 0110674. ISSN: 0042-6822.
AU Mak I; Mak S; Benchimol S
AN 88160048 MEDLINE

L122 ANSWER 104 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI **Human** immunodeficiency virus gag-gene expression in a
recombinant vaccinia virus
SO Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya (1988), (9), 36-9
CODEN: MGMVDU; ISSN: 0208-0613
AU Popov, S. A.; Barsov, E. V.; Bukrinskii, M. I.; Zhdanov, V. M.
AN 1988:623907 HCAPLUS
DN 109:223907

L122 ANSWER 105 OF 115 HCAPLUS COPYRIGHT 2003 ACS
TI Organization of the **human** p53 gene. I. Molecular cloning of
the **human** p53 gene
SO Genetika (Moscow) (1987), 23(9), 1547-54, 12 plates

CODEN: GNKAA5; ISSN: 0016-6758

AU Bukhman, V. L.; Ninkina, N. N.; Chumakov, P. M.; Khilenkova, M. A.;
Samarina, O. P.; Georgiev, G. P.

AN 1987:612800 HCAPLUS

DN 107:212800

L122 ANSWER 106 OF 115 HCAPLUS COPYRIGHT 2003 ACS

TI Molecular organization of a complete gene coding the **human**
cellular tumor antigen (p53)

SO Doklady Akademii Nauk SSSR (1987), 292(1), 223-6 [Genet.]
CODEN: DANKAS; ISSN: 0002-3264

AU Bukhman, V. L.; Ninkina, N. N.; Samarina, O. P.; Matveeva, O. V.;
Chumakov, P. M.; Georgiev, G. P.

AN 1987:114537 HCAPLUS

DN 106:114537

L122 ANSWER 107 OF 115 HCAPLUS COPYRIGHT 2003 ACS

TI Characterization of the **human** p53 gene

SO Molecular and Cellular Biology (1986), 6(5), 1379-85
CODEN: MCEBD4; ISSN: 0270-7306

AU Lamb, Peter; Crawford, Lionel

AN 1986:419667 HCAPLUS

DN 105:19667

L122 ANSWER 108 OF 115 MEDLINE DUPLICATE 59

TI Expression of p53 in **human** leukemia and lymphoma.

SO BLOOD, (1986 Jul) 68 (1) 113-8.
Journal code: 7603509. ISSN: 0006-4971.

AU Prokocimer M; Shaklai M; Bassat H B; Wolf D; Goldfinger N; Rotter V

AN 86243647 MEDLINE

L122 ANSWER 109 OF 115 MEDLINE DUPLICATE 60

TI In vitro expression of **human** p53 cDNA clones and
characterization of the cloned **human** p53 gene.

SO MOLECULAR AND CELLULAR BIOLOGY, (1985 Aug) 5 (8) 1887-93.
Journal code: 8109087. ISSN: 0270-7306.

AU Wolf D; Laver-Rudich Z; Rotter V

AN 86310859 MEDLINE

L122 ANSWER 110 OF 115 HCAPLUS COPYRIGHT 2003 ACS

TI Molecular cloning and in vitro expression of a cDNA clone for
human cellular tumor antigen p53

SO Molecular and Cellular Biology (1985), 5(7), 1601-10
CODEN: MCEBD4; ISSN: 0270-7306

AU Harlow, Ed; Williamson, Nicola M.; Ralston, Robert; Helfman, David M.;
Adams, Timothy E.

AN 1985:482693 HCAPLUS

DN 103:82693

L122 ANSWER 111 OF 115 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 61

TI The amino acid sequence of murine p53 determined from a c-DNA clone.

SO Virology, (1984) 134/2 (477-482).
CODEN: VIRLAX

AU Pennica D.; Goeddel D.V.; Hayflick J.S.; et al.

AN 84132393 EMBASE

L122 ANSWER 112 OF 115 HCAPLUS COPYRIGHT 2003 ACS

TI Molecular analysis of the gene for the p53 cellular tumor antigen

SO Cancer Cells (1984-1989) (1984), 2(Oncog. Viral Genes), 383-91
CODEN: CACEEG; ISSN: 0743-2194

AU Benchimol, S.; Jenkins, J. R.; Crawford, L. V.; Leppard, K.; Lamb, P.;
Williamson, N. M.; Pim, D. C.; Harlow, E.

AN 1984:623833 HCAPLUS

DN 101:223833

L122 ANSWER 113 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 TI Antibodies of predetermined specificity for the amino terminus of a cellular protein p53 react with the native molecule: evidence for the presence of different p53s
 SO Proceedings of the National Academy of Sciences of the United States of America (1983), 80(5), 1199-203
 CODEN: PNASA6; ISSN: 0027-8424
 AU Luka, Janos; Sternaas, Lars; Joernvall, Hans; Klein, George; Lerner, Richard
 AN 1983:177296 HCAPLUS
 DN 98:177296

L122 ANSWER 114 OF 115 MEDLINE DUPLICATE 62
 TI Characterization of **human** p53 antigens employing primate specific monoclonal antibodies.
 SO VIROLOGY, (1983 Dec) 131 (2) 502-17.
 Journal code: 0110674. ISSN: 0042-6822.
 AU Thomas R; Kaplan L; Reich N; Lane D P; Levine A J
 AN 84099542 MEDLINE

L122 ANSWER 115 OF 115 MEDLINE DUPLICATE 63
 TI Variation in antigenic determinants of p53 transformation-related protein obtained from various species.
 SO JOURNAL OF IMMUNOLOGY, (1983 Jul) 131 (1) 329-33.
 Journal code: 2985117R. ISSN: 0022-1767.
 AU Rotter V; Friedman H; Katz A; Zerivitz K; Wolf D
 AN 83239853 MEDLINE

=> d ab 5,8,16,32,35,36,43,56,57,73

L122 ANSWER 5 OF 115 MEDLINE DUPLICATE 3
 AB The 90-kDa cellular protein encoded by the mouse mdm-2 oncogene binds to the p53 protein in vivo and inhibits its transactivation function (J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine, Cell 69:1237-1245, 1992). cDNA clones encoding the **human** homolog of the mdm-2 protein (also called hdm-2) were isolated from a HeLa cell cDNA library. A series of monoclonal antibodies have been generated against **human** mdm-2 protein, and the epitopes recognized by these antibodies have been mapped. By construction of a series of deletion mutants, the region of the mdm-2 protein that is critical for complex formation with the **p53** protein has been mapped to the N-terminal **portion** of the **human** mdm-2 protein. Interestingly, a monoclonal antibody with an epitope located in this same region failed to immunoprecipitate the mdm-2-p53 complex and appeared to recognize only free mdm-2 protein. The domain of the p53 protein that is sufficient for interaction with **human** mdm-2 protein has been mapped to the N-terminal 52 amino acid residues of the p53 protein. This region contains the transactivation domain of p53, suggesting that mdm-2 may inhibit p53 function by disrupting its interaction with the general transcription machinery.

L122 ANSWER 8 OF 115 HCAPLUS COPYRIGHT 2003 ACS
 AB An immune selection procedure was employed in order to isolate p53 binding sites from mouse genomic DNA. Two DNA clones capable of tight specific interaction with wild type p53 were subjected to further characterization. In both cases, the p53 binding regions displayed a high degree of sequence homol. with the consensus binding site defined for **human** genomic DNA. One of the clones was derived from the LTR of a retrovirus-like element (a member of the GLN family). The region encompassing the GLN LTR p53 binding site could confer p53 responsiveness upon a heterologous promoter. Furthermore, the expression of the endogenous, chromosomally integrated GLN elements was significantly induced upon activation of wild

type p53 in cells harboring a temp.-sensitive p53 mutant. Finally, it was demonstrated that p53-MDM2 complexes fail to bind tightly to such a p53 binding site. This may contribute to the inhibition by MDM2 of p53-mediated transcriptional activation.

L122 ANSWER 16 OF 115 MEDLINE DUPLICATE 12
AB The central role of the p53 tumor suppressor gene product in oncogenesis is gradually being clarified. Point mutations in the p53 tumor suppressor gene are common in most **human** cancers and are often associated with p53 protein overexpression. Overexpressed wild-type or mutant determinants of the p53 protein thus represent an attractive target for immunotherapy of cancer directed against a structure involved in malignant transformation. An important step towards this goal is identification of epitopes of p53 that can be recognized by **human** cytotoxic T lymphocytes. We identified **peptides** of (mutant) **p53** capable of binding to HLA-A2.1 in an in vitro assay. These HLA-A2.1-binding peptides were utilized for in vitro induction of primary cytotoxic T lymphocyte responses using a **human** processing-defective cell line (174CEM.T2) as antigen-presenting cell. These cells display "empty" HLA class I surface molecules, that can efficiently be loaded with a single peptide. We obtained CD8+ cytotoxic T lymphocyte clones capable of specifically lysing target cells loaded with wild-type or tumor-specific mutant **p53 peptides**. This strategy allows the in vitro initiation of **human** cytotoxic T lymphocyte responses against target molecules of choice.

L122 ANSWER 32 OF 115 HCAPLUS COPYRIGHT 2003 ACS
AB The authors screened the **human** p53 tumor suppressor sequence for HLA-A2 motifs and identified 10 nonameric peptide sequences with Leu or Met at position 2 and Ala, Ile, or Val at position 9. These **peptides** exhibited homol. solely to **p53** sequences of various species and not to other proteins listed in SwissProt. In addn., B-cell lines expressing HLA-A2 were loaded with these peptides and cell lysis was obsd. by a melanoma-derived infiltrating lymphocyte.

L122 ANSWER 35 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

L122 ANSWER 36 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

L122 ANSWER 43 OF 115 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AB Mutations in the p53 gene are most frequent in cancer. Many p53 mutants possess transforming activity in vitro. In cells transformed by such mutants, the mutant protein is oligomerized with endogenous cell p53. To determine the relevance of oligomerization for transformation, miniproteins containing C-terminal **portions** of **p53** were generated. These miniproteins, although carrying no point mutation, transformed at least as efficiently as full-length mutant p53. Transforming activity was coupled with the ability to oligomerize with wild-type p53, as well as with the ability to abrogate sequence-specific DNA binding by coexpressed wild-type p53. These findings suggest that p53-mediated transformation may operate through a dominant negative mechanism, involving the generation of DNA binding-incompetent oligomers.

L122 ANSWER 56 OF 115 MEDLINE DUPLICATE 36
AB Somatic mutation of the p53 gene is a very frequent event in the development of **human** neoplasia, and germ line mutations in p53 are responsible for an inherited cancer susceptibility syndrome. Many of the mutations in p53 found in **human** tumours are point mutations that result in the substitution of a single amino acid in the protein. These point mutant proteins are much more stable than the normal protein and the mutant product accumulates to a high level which permits important information about p53 expression to be obtained by immunochemical analysis. Using bacterial expression systems to produce **fragments** of **human p53** we have isolated and characterized new

monoclonal antibodies to p53. These antibodies are suitable for the measurement of p53 in ELISA, immunoblotting and immunoprecipitation analyses. They are especially useful in immunohistochemistry as they are able to react strongly with p53 in conventionally fixed and processed histological sections.

L122 ANSWER 57 OF 115 MEDLINE

AB Products of a number of mutant p53 genes bind with high affinity to members of the hsp70 family of chaperonin proteins, whereas wild type p53 lacks this type of association. Examination of the sequences of p53 genes from five different species enabled us to predict domains on p53 which may be involved in the association with hsp70 family members. A synthetic polypeptide (Pro-17-Gly) corresponding to the candidate hsp70 binding domain bound to in vitro translated hsp70 as determined by affinity chromatography and nondenaturing gel mobility shift assays. In addition, the Pro-17-Gly **peptide** competitively inhibited association between hsp70 and **p53**, an activity which was determined by immunoprecipitation with anti-p53 monoclonal antibody PAb240. The data indicate that p53 contains a hsp70 binding domain, which is located in a highly conserved region at the amino terminus of the protein, and may participate in the cellular function of wild-type p53 or in the transforming capacity of p53 mutants.

L122 ANSWER 73 OF 115 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 44

AB Synthetic peptide substrates for the cell division cycle regulated protein kinase, p34cdc2, have been developed and characterized. These peptides are based on the sequences of two known substrates of the enzyme, Simian Virus 40 Large T antigen and the **human** cellular recessive oncogene product, **p53**. The **peptide** sequences are H-A-D-A-Q-H-A-T-P-P-K-K-K-R-K-V-E-D-P-K-D-F-OH (T antigen) and H-K-R-A-L-P-N-N-T-S-S-S-P-Q-P-K-K-K-P-L-D-G-E-Y-NH₂ (p53), and they have been employed in a rapid assay of phosphorylation in vitro. Both peptides show linear kinetics and an apparent K(m) of 74 and 120- μ M, respectively, for the purified **human** enzyme. The T antigen peptide is specifically phosphorylated by p34cdc2 and not by seven other protein serine/threonine kinases, chosen because they represent major classes of such enzymes. The peptides have been used in whole cell lysates to detect protein kinase activity, and the cell cycle variation of this activity is comparable to that measured with specific immune and affinity complexes of p34cdc2. In addition, the peptide phosphorylation detected in mitotic cells is depleted by affinity adsorption of p34cdc2 using either antibodies to p34cdc2 or by immobilized p13, a p34cdc2-binding protein. Purification of peptide kinase activity from mitotic HeLa cells yields an enzyme indistinguishable from p34cdc2. These peptides should be useful in the investigation of p34cdc2 protein kinases and their regulation throughout the cell division cycle.

=> d ab 113

L122 ANSWER 113 OF 115 HCAPLUS COPYRIGHT 2003 ACS

AB Two synthetic peptides corresponding to residues 1-20 and 10-20, resp., of 1 type of a transformation-assocd., DNA- and antigen-binding cellular protein called p53 have been linked to a carrier protein and injected into rabbits to raise antibodies. The antibodies obtained were capable of reacting with the native protein, as judged by an ELISA, protein A-linked staining of immunoblots after SDS gel electrophoresis, and immunopptn. The immunoassay titers against the protein were lower for these antibodies than for antisera derived from immunization with purified p53. However, staining with the immunoblot method showed that the anti-peptide antibodies against p53 were uniquely specific. The data suggest that at least 2 different types of p53 mols. occur. The cellular protein previously isolated from **human** cells transformed by Epstein-Barr virus and from murine tumors induced by methylcholanthrene appears to be larger than

the p53 reported in relation to simian virus 40- or adenovirus-transformed cells and to some other tumors. Some interrelationships have not been excluded, but it is clear that the 2 protein mols. do not behave identically. The reactions of the anti-peptide antibodies with the intact protein have implications in regard to protein conformations. The strict specificities of such antibodies allow the generation of distinct sets of reagents useful for quantitation, purification, and cloning.

=> d ab 1-4,13,16-19,23-26,28,30,33,35-40,42-44,46 149

L49 ANSWER 1 OF 46 MEDLINE DUPLICATE 1

AB The serum response factor (SRF) is a 67-kDa phosphoprotein that, together with auxiliary factors, modulates transcription of immediate early genes containing serum response elements in their promoters. Here we show that the carboxyl-terminal domain of human SRF is phosphorylated in vivo and is recognized in vitro by the double-stranded DNA-activated serine/threonine-specific protein kinase, **DNA-PK**. SRF phosphorylation by **DNA-PK** was stimulated by its cognate binding site. Protein microsequence analysis of a 22-amino acid synthetic SRF peptide and phosphopeptide analysis of genetically altered glutathione S-transferase-SRF fusion proteins identified Ser-435 and Ser-446 of human SRF as sites phosphorylated by **DNA-PK**. Both serines are followed by glutamine. Changing Gln-436 and Gln-447 to other residues reduced or eliminated phosphorylation by **DNA-PK**, confirming that these glutamines are important determinants for kinase recognition. The carboxyl-terminal transcription activation domain was mapped within a 71-amino acid region that contains both **DNA-PK** phosphorylation sites. Amino acid substitutions that interfered with phosphorylation by **DNA-PK** at Ser-435/446 in GAL4-SRF fusion proteins were reduced in transactivation potency. From these data we suggest that **DNA-PK** phosphorylation may modulate SRF activity in vivo.

L49 ANSWER 2 OF 46 MEDLINE

AB Interaction of viral oncoproteins, such as SV40 large T, with cellular growth suppressor proteins Rb and p53 is presumed to inactivate or modulate their growth suppression functions, thereby leading to transformation. An additional transformation-related activity of LT leads to hyperphosphorylation of p53. To search for kinases that might be responsible for this effect, p53-LT complexes were immunopurified from different SV40-transformed rat cell lines and assayed for associated kinase activities, in vitro. Protein kinase activity was readily observed in p53-LT immunocomplexes from wild-type transformed cells but was low or undetectable in p53 from mutant-transformed or normal cells. Optimal activity required the presence of Mn⁺⁺. p53 was phosphorylated at all sites found in vivo. In contrast, LT was phosphorylated only at a subset of formerly identified sites and at additional sites not seen in vivo. The p53-LT-kinase complex was assayed for the presence of casein kinases, cdk like kinases, or DNA-activated kinase, using specific effectors, antibodies, or purified enzymes as tools. DNA-activated kinase or cdc2/cdk2 were not detectable, although the purified enzymes phosphorylated p53 in vitro. Casein kinase 2 represented the major activity, which on p53 phosphorylated not only the C-terminal Ser390 but also several sites in the N-terminal region. One additional activity, not identified so far, may represent an LT-induced or activated kinase. This kinase seems to enhance overall phosphorylation of p53 and, perhaps other substrates, and may thereby contribute to transformation.

L49 ANSWER 3 OF 46 MEDLINE DUPLICATE 2

AB Overexpression of wild-type p53 prevents cells from entering the S phase of the cell cycle. The amino-terminal transactivation region of p53 is phosphorylated by several protein kinases, including **DNA-PK**, a nuclear serine/threonine protein kinase that in vitro

requires DNA for activity. **DNA-PK** was recently shown to phosphorylate serines 15 and 37 of human p53 (Lees-Miller et al., 1992. Mol. Cell. Biol., 12, 5041-5049). To prevent phosphorylation at these sites, mutants were constructed that changed the codons for serine 15 or serine 37 to alanine codons. Expression of p53-Ala-37 in stably transformed T98G cells blocked progression of the cells into S phase as well as did the expression of wild-type p53. In contrast, p53-Ala-15 was partially defective in blocking cell cycle progression. Several cell clones transformed with the mutant p53-Ala-15 gene expressed normal levels of p53 mRNA but accumulated little or no detectable p53 protein. However, by using a transient expression system driven by a strong cytomegalovirus promoter, we showed that the inability of p53-Ala-15 to fully block cell cycle progression was not due to inadequate levels of expression or to a failure of the mutant protein to accumulate in the nucleus. These results suggest that phosphorylation of Ser-15 may affect p53 function.

L49 ANSWER 4 OF 46 MEDLINE DUPLICATE 3

AB The DNA-dependent protein kinase (**DNA-PK**) phosphorylates a number of transcription factors. Here, we show that the **DNA-PK** modifies c-Jun in vitro and that serine residue 249 (Ser-249) is required for phosphorylation to occur. This residue corresponds to one of three sites of c-Jun that are phosphorylated in vivo and which negatively regulate c-Jun DNA binding in vitro. However, we find that phosphorylation of c-Jun by the **DNA-PK** does not interfere with DNA binding, indicating that phosphorylation at other sites is required for this effect. Mutagenesis of the phosphorylated region of c-Jun reveals that the primary amino acid sequence recognised by the **DNA-PK** consists of the sequence Ser-Gln, and that adjacent acidic residues potentiate kinase activity. Furthermore, when this site is placed within the context of a second protein, it confers **DNA-PK** directed phosphorylation upon that protein. Our findings will facilitate identification of **DNA-PK** phosphorylation sites in other transcription factors.

L49 ANSWER 13 OF 46 MEDLINE

L49 ANSWER 16 OF 46 MEDLINE DUPLICATE 7

L49 ANSWER 17 OF 46 SCISEARCH COPYRIGHT 2003 THOMSON ISIDUPLICATE 8

L49 ANSWER 18 OF 46 MEDLINE DUPLICATE 9

AB The DNA-dependent protein kinase (**DNA-PK**) phosphorylates Sp1 and several other nuclear proteins. Here, we show that Sp1 and the **DNA-PK** must be colocalized on the same DNA molecule for efficient phosphorylation to occur. Interestingly, we find that the **DNA-PK** binds to and is activated by the ends of DNA molecules. Furthermore, we show that the DNA binding properties of the **DNA-PK** are identical to those of Ku, a well-characterized human autoimmune antigen. We demonstrate that the **DNA-PK** can be fractionated into two components, one of which is Ku and the other of which is a polypeptide of approximately 350 kd. DNA cross-linking and coimmunoprecipitation studies indicate that the catalytic 350 kd **DNA-PK** component is directed to DNA by protein-protein interactions with Ku. The implications of the unusual DNA binding mode and multicomponent nature of the **DNA-PK** are discussed.

L49 ANSWER 19 OF 46 MEDLINE DUPLICATE 10

AB Nuclear extracts prepared from human leukemic cells grown in the presence of cell differentiation-inducing agents showed a significant increase in the phosphorylation of a nuclear protein referred to as NP-72. The NP-72 phosphorylation was greatly increased by the addition of purified HeLa **DNA-PK** and was reduced by the inclusion of a **DNA-PK**-specific monoclonal antibody to the assay mixture.

Phosphoamino acid analysis showed serine (60%) and threonine (40%) residues to be the phosphate acceptors. Western blot analysis of control and TPA-treated nuclear extracts detected multiple immunoreactive protein bands. The two most prominent species migrated as 300- and 210-kD proteins on SDS-PAGE, possibly representing an intact and a processed form of **DNA-PK**. The 300-kD form of **DNA-PK** was only detected in TPA-treated nuclear extracts, raising the possibility that cell differentiation is associated with the down-regulation and/or the inhibition of a protease(s) capable of regulating **DNA-PK** turnover.

- L49 ANSWER 23 OF 46 MEDLINE DUPLICATE 12
 AB Alzheimer Disease (AD) is a distinct form of dementia characterized by the occurrence of neurofibrillary tangles, neurotic plaques and loss of certain neuronal populations. The tangles are associated with the presence of abnormal proteinaceous deposits. One such protein, referred to as tau, is found to be excessively phosphorylated in AD. We demonstrate that a double-stranded DNA-stimulated protein kinase (referred to as **DNA-PK**) effectively catalyzes the phosphorylation of recombinant human protein tau. Moreover, in the presence of stimulatory DNA, the hyperphosphorylation of tau is accompanied by a significant shift in its mobility on SDS polyacrylamide gels. These results suggest that **DNA-PK** may contribute to the pathogenesis of AD.
- L49 ANSWER 24 OF 46 MEDLINE DUPLICATE 13
 AB Human **DNA-PK** is a nuclear, serine/threonine protein kinase that, when activated by DNA, phosphorylates several DNA-binding substrates, including the tumor suppressor protein p53. To identify which p53 residues are phosphorylated, we examined **DNA-PK**'s ability to phosphorylate synthetic peptides corresponding to human p53 sequences. Serines 15 and 37 in the amino-terminal transactivation domain of human p53, and serines 7 and 18 of mouse p53, were phosphorylated by **DNA-PK** in the context of synthetic peptides. Other serines in these p53 peptides, and serines in other p53 peptides, including peptides containing the serine 315 p34cdc2 site and the serine 392 casein kinase II site, were not recognized by **DNA-PK** or were phosphorylated less efficiently. Phosphorylation of the conserved serine 15 in human p53 peptides depended on the presence of an adjacent glutamine, and phosphorylation was inhibited by the presence of a nearby lysine. Phosphorylation of recombinant wild-type mouse p53 was inhibited at high DNA concentrations, suggesting that **DNA-PK** may phosphorylate p53 only when both are bound to DNA at nearby sites. Our study suggests that **DNA-PK** may have a role in regulating cell growth and indicates how phosphorylation of serine 15 in DNA-bound p53 could alter p53 function.
- L49 ANSWER 25 OF 46 MEDLINE DUPLICATE 14
 AB Phosphorylation is an attractive mechanism for regulating the functions of p53. The p34cdc2 kinase, which is involved in regulation of the cell cycle, phosphorylates serine-315 of human p53 in vitro. Casein kinase II phosphorylates serine-389 of mouse p53 in vitro. The amino-terminal region of mouse p53 contains a cluster of potential serine phosphorylation sites. Those sites have been proposed to be sites for phosphorylation by a double-stranded DNA-dependent kinase (**DNA-PK**) from HeLa cells and can be dephosphorylated by protein phosphatase 2A. To identify in vivo phosphorylation sites in the amino-terminal region of mouse p53, we mutated potential phosphorylation sites and analyzed the mutant proteins by tryptic phosphopeptide mapping. We identified serine-7, -9, -18, and -37 as in vivo phosphorylation sites. We further showed that mouse p53 expressed in bacteria is phosphorylated by **DNA-PK** on amino-terminal serine residues in vitro.
- L49 ANSWER 26 OF 46 MEDLINE DUPLICATE 15

AB Autophosphorylation of a **DNA-activated protein kinase (DNA-PK)** in Raji Burkitt's lymphoma cells generated a band that corresponded to a phosphoprotein of about 300 kDa on SDS/PAGE. This band corresponds to a 300-350-kDa **DNA-PK** found previously in HeLa cells. In addition to the 300-kDa phosphoprotein, the band of a highly phosphorylated 58-kDa protein was detected by SDS/PAGE of partially purified **DNA-PK** preparations after the phosphorylation reaction in the presence of double-stranded DNA. This phosphoprotein was specifically immunoprecipitated by phosphoprotein nor detectable activities of other kinases, phosphorylated recombinant c-Myc proteins in the presence of DNA. The c-Myc phosphorylation by **DNA-PK** was markedly stimulated by relaxed, double-stranded DNA, but neither by single-stranded DNA nor by RNA. Phosphopeptide mapping and phosphoamino acid analysis indicated that **DNA-PK** phosphorylates c-Myc in vitro at several serine residues.

L49 ANSWER 28 OF 46 MEDLINE DUPLICATE 16

AB The **DNA-activated protein kinase (DNA-PK)** is a nuclear serine/threonine protein kinase that phosphorylates DNA-binding proteins, including several transcription factors. **DNA-PK** is one of a very few enzymes known to be regulated through interaction with DNA that does not have DNA as a template or substrate. We suggest that **DNA-PK** may function in cell homeostasis, in part through the modulation of transcriptional activity.

L49 ANSWER 30 OF 46 LIFESCI COPYRIGHT 2003 CSA

AB The DNA-dependent protein kinase (**DNA-PK**) phosphorylates Sp1 and several other nuclear proteins. We show that Sp1 and the **DNA-PK** must be colocalized on the same DNA molecule for efficient phosphorylation to occur. We find that the **DNA-PK** binds to and is activated by the ends of DNA molecules. We show that the DNA binding properties of the **DNA-PK** are identical to those of Ku, a well-characterized human autoimmune antigen. We demonstrate that the **DNA-PK** can be fractionated into two components, one of which is Ku and the other of which is a polypeptide of approximately 350 kd. DNA cross-linking and coimmunoprecipitation studies indicate that the catalytic 350 kd **DNA-PK** component is directed to DNA by protein-protein interactions with Ku.

L49 ANSWER 33 OF 46 MEDLINE DUPLICATE 18

AB We have reported previously that chicken progesterone receptor (PR) is phosphorylated in vivo in response to progesterone administration. Three phosphorylation sites have been reported, two of which show increased phosphorylation in response to hormone and one which is phosphorylated only in response to hormone administration. We found previously that PR lacking the hormone-dependent phosphorylation is active in an in vitro transcription assay. Since the source of general transcription factors is a HeLa nuclear extract which contains many kinases, we have analyzed the receptor for phosphorylation during the in vitro transcription assay. We report here that the receptor is rapidly and efficiently phosphorylated on new sites, causing a change in receptor mobility on sodium dodecyl sulfate-gels. This phosphorylation is strictly dependent upon the presence of double stranded DNA. A **DNA-activated protein kinase** with similar properties has been isolated previously from HeLa cell nuclei. We find that phosphorylation of PR with this purified enzyme mimics the phosphorylation observed in the transcription assay. These data suggest that a previously undetected additional series of DNA-dependent phosphorylations may be required for activation of the PR.

L49 ANSWER 35 OF 46 MEDLINE DUPLICATE 19

AB Protein phosphorylation modulates the functions of simian virus 40 large T antigen (TAG) in productive and transforming infections. We recently described a **DNA-activated protein kinase (DNA-PK)** that efficiently phosphorylates TAG and several other nuclear, DNA-binding proteins in vitro (S.P. Lees-Miller, Y.-R. Chen, and C. W. Anderson, Mol. Cell. Biol. 10:6472-6481, 1990). In this report, we show by direct amino acid sequence analysis that **DNA-PK** phosphorylates TAG strongly at Ser-677, a residue known to be important for TAG interaction with origin site I and for transformation. We propose that **DNA-PK** may modulate the role of TAG in repressing early viral transcription and cell transformation, but a role for **DNA-PK** in regulating simian virus 40 DNA synthesis is not excluded. **DNA-PK** also phosphorylates Ser-665, and Ser-667, and one or more serines between amino acids 110 and 131. At least six serines, Ser-111, Ser-112, Ser-120, Ser-665, Ser-667, and Ser-677, are phosphorylated in TAG purified from baculovirus vector-infected insect cells.

L49 ANSWER 36 OF 46 MEDLINE DUPLICATE 20

AB **DNA-PK** is a moderately abundant serine/threonine protein kinase found in the nucleus of a wide range of eukaryotic cells. It is one of the few known cellular enzymes whose activity is regulated directly by DNA. Many DNA binding proteins, including a number of transcription factors, are substrates for **DNA-PK** in vitro. We suggest that this kinase may coordinate signal transduction pathways and nuclear events, including transcription, in response to changes in DNA or chromatin state.

L49 ANSWER 37 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

L49 ANSWER 38 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE 21

L49 ANSWER 39 OF 46 MEDLINE DUPLICATE 22

AB HeLa cells contain a serine/threonine protein kinase (**DNA-PK**) that is strongly activated in vitro by low concentrations of double-stranded DNA (dsDNA). Activation was specific for dsDNA; both natural DNAs and synthetic oligonucleotides functioned as kinase activators. The fact that **DNA-PK** activity was rapidly inhibited by incubation with dsDNA and ATP suggests that **DNA-PK** activity also may be regulated by autophosphorylation. During gel filtration, **DNA-PK** activity behaved as a 350-kDa protein, and highly purified **DNA-PK** contained a dsDNA-binding, 350-kDa polypeptide that was phosphorylated in a dsDNA-dependent manner. We conclude that this 350-kDa polypeptide is likely to be **DNA-PK**. Previously we showed that the dsDNA-activated kinase phosphorylates two threonines at the N terminus of hsp90 alpha (S. P. Lees-Miller and C. W. Anderson, J. Biol. Chem. 264:17275-17280, 1989). Here we show that **DNA-PK** also phosphorylates the simian virus 40 large tumor antigen, the mouse tumor-suppressor protein p53, the human Ku autoantigen, and two unidentified HeLa DNA-associated polypeptides of 52 and 110 kDa. Identification of these and other newly identified DNA-binding substrates suggest that the dsDNA-activated kinase may regulate transcription, DNA replication, or cell growth.

L49 ANSWER 40 OF 46 MEDLINE DUPLICATE 23

AB A **DNA-activated protein kinase (DNA-PK)** was purified from nuclei of HeLa cells. Activity was associated with a single high-molecular-mass (approximately-300,000 Da) polypeptide when analyzed by gel filtration, denaturing polyacrylamide gel electrophoresis, and Western immunoblotting using a monoclonal antibody that also inhibits enzyme activity. Nuclear

localization was indicated by subcellular fractionation and confirmed by immunofluorescence on whole cells. Double-stranded DNA stimulated phosphorylation of the 300-kDa polypeptide in purified preparations as well as phosphorylation of the exogenous substrates alpha-casein, simian virus 40 large T antigen, and the human heat shock protein hsp90. Autophosphorylation led to inactivation of the enzyme. The phosphorylation of casein was stimulated over 30-fold by DNA and was specific for serine and threonine residues. Bovine serum albumin and histone H1 were poor substrates for **DNA-PK**, and no phosphorylation of immunoglobulin G or histones other than H1 was observed. Supercoiled or heat-denatured DNA and synthetic double-stranded RNA or RNA-DNA copolymers did not stimulate casein phosphorylation by **DNA-PK**. Interaction of the enzyme with DNA in the absence of exogenous substrates was demonstrated by thermal inactivation and gel mobility shifts. These characteristics identify **DNA-PK** as distinct from other protein kinases described in the literature and suggest that activation by DNA is an important feature of the enzyme's in vivo function.

L49 ANSWER 42 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

L49 ANSWER 43 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

L49 ANSWER 44 OF 46 MEDLINE DUPLICATE 24

AB The 90-kDa heat-shock protein, hsp90, is an abundant cytoplasmic protein that can be phosphorylated in vitro by a double-stranded (ds) **DNA-activated protein kinase** found in cells from several species. Here we show that the dsDNA-activated protein kinase from human HeLa cells phosphorylates 2 threonine residues in the sequence PEETQTQDQPM at the amino terminus of human hsp90 alpha. Hsp90 beta, which is 97% identical to hsp90 alpha but lacks both amino-terminal threonines, is not phosphorylated by the dsDNA-activated protein kinase. Mouse hsp86 and rabbit hsp90 alpha are homologous to human hsp90 alpha; both heterologous proteins are phosphorylated at the same amino-terminal threonines by the human dsDNA-activated protein kinase.

L49 ANSWER 46 OF 46 NTIS COPYRIGHT 2003 NTIS

AB Short communication.

=> d all 46 149

L49 ANSWER 46 OF 46 NTIS COPYRIGHT 2003 NTIS

AN 1991(13):02854 NTIS Order Number: DE90016556/XAB

TI SV40 large tumor antigen and the tumor suppressor p53 are phosphorylated by a **DNA-activated protein kinase** from human cells.

AU Lees-Miller, S. P.; Chen, Y. R.; Anderson, C. W.

CS Brookhaven National Lab., Upton, NY.

Sponsor: Department of Energy, Washington, DC. (004545000 0936000)

NR DE90016556/XAB; BNL-43799, BIO-4569; CONF-9007160-1
4p; 1990

NC Contract(s): AC02-76CH00016

DT Report

CY United States

LA English

NTE International conference on methods in protein sequence analysis (8th), Kiruna (Sweden), 1-7 Jul 1990. Sponsored by Department of Energy, Washington, DC.

AV Portions of this document are illegible in microfiche products. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

NTIS Prices: PC A01/MF A01
 OS GRA&I9102; ERA9102
 AB Short communication.
 CC 57B Biochemistry
 57F Cytology, genetics, and molecular biology
 57J Immunology
 CT *Phosphoproteins; *DNA; Amino Acids; Animal Cells; Biological
 Functions; Cell Differentiation; Gene Regulation; Growth; In Vitro;
 Inhibition; Neoplasms; Oncogenes; Phosphorylation; Protein Structure;
 Meetings
 *SV40; *PROTEIN KINASES; *VIRAL ANTIGENS; EDB/550200

=> log y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 29.78 | 294.86 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -1.95 | -1.95 |

STN INTERNATIONAL LOGOFF AT 11:44:32 ON 06 JUN 2003